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ABSTRACT 
Background: Chest pain is one of the most common symptoms in patients presenting to the 
emergency department (ED). Identifying the minority of patients with an acute coronary 
syndrome (ACS) is a challenge. The introduction of high-sensitivity cardiac troponin (hs-cTn 
T and I) assays has radically improved the assessment. The aim of this thesis was to evaluate 
four methods of assessing patients presenting with suspected ACS in the era of hs-cTn. 
Methods and results: In Study I, we retrospectively evaluated the value of predischarge 
exercise ECG testing in 951 chest pain patients in whom myocardial infarction (MI) had been 
ruled out by means of hs-cTnT. We found no significant differences regarding death or MI 
between patients with a positive or a negative test, neither at 90 (n=1 [1.1%] vs. n=1 [0.2%]), 
nor at 365 days (n=2 [2.1%] vs. n=4 [0.7%]) of follow-up. In total, there were 9 (0.9%) 
deaths and 10 (1.1%) MIs within 365 days. The one-year rates of death (1.3%) and MI (0.5%) 
in a matched Swedish population were comparable. 
Study II was a retrospective evaluation of the diagnostic sensitivity of an undetectable level 
of hs-cTnT at presentation, with and without information from the electrocardiogram (ECG), 
to rule out MI in a non-ST-segment elevation MI (NSTEMI) population presenting early. 
Twenty-four (2.6%) of the 911 early presenting NSTEMI patients initially had an 
undetectable level of hs-cTnT. In patients presenting >1–≤2 hours from symptom onset, the 
sensitivity for MI when combining hs-cTnT and ECG was 99.4% (95% confidence interval 
[CI] 98.4%–99.8%). In patients presenting ≤1 hour from symptom onset and in patients aged 
≤65 years without prior MI, the sensitivity was insufficient. NSTEMI patients presenting with 
an undetectable level of hs-cTnT were younger but had a similar 30-day outcome to NSTEMI 
patients presenting with a detectable level of hs-cTnT. 
In Study III, we retrospectively evaluated a one-hour hs-cTnT algorithm in 1,091 chest pain 
patients with a non-elevated hs-cTnT when presenting to the ED and examined early dynamic 
changes in hs-cTnT. Dynamic one-hour changes (Δ ≥3 ng/L) occurred in 23 patients (2.1%). 
Fifteen patients (65.2%) in the dynamic group were admitted, compared to 148 patients 
(13.9%) in the non-dynamic group (p<0.001). Four of the patients admitted (26.7%) in the 
dynamic and one (0.7%) in the non-dynamic group were diagnosed with an MI (p<0.001). 
No death or MI occurred within 30 days among those discharged from the ED. 
In Study IV, we evaluated the clinical effects of implementing a one-hour hs-cTnT or I 
algorithm combined with the HEART score in a prospective observational before-after study 
including 1,233 patients at six centres. The new strategy was associated with a reduction in 
admission rate (59% to 33%, p<0.001, adjusted odds ratio [95% CI]: 0.33 [0.25–0.42]), 
median time to discharge (23.2 to 4.7 hours, p<0.001) and median health care-related costs 
(€1,651 to €1,019, p<0.001). The rates of death and MI were very low. 
Conclusions: Rapid hs-cTn algorithms improve the prognostic assessment in patients with 
suspected ACS, making routine admission and predischarge exercise ECG testing redundant. 
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1 RESEARCH QUESTION AND RATIONALE 
 
Chest pain is one of the most common symptoms in patients presenting to the emergency 
department (ED)
1 2
. It is also the most common symptom in patients with an ongoing acute 
coronary syndrome (ACS), i.e. myocardial infarction (MI) or unstable angina pectoris 
(UAP)
3
. Traditionally, about 40% of chest pain patients have been admitted to hospital, but 
only 5–20%, depending on definitions, of those presenting with chest pain, are eventually 
diagnosed with an ongoing ACS
4-7
. Some patients are diagnosed with other serious 
conditions such as pulmonary embolism or aortic dissection, but the vast majority are 
discharged with a benign diagnosis such as non-specific chest pain
3 8
. On the other hand, 
about 1% of chest pain patients discharged directly from the ED experience a major adverse 
cardiac event (MACE) within 30 days of follow-up
9
. 
The introduction of high-sensitivity cardiac troponin (hs-cTn) assays in routine clinical care 
in 2010 has markedly improved the reliability of early testing in patients presenting with 
symptoms suggestive of ACS, and several algorithms for early identification of ACS have 
been developed and validated
10-16
. However, large prospective studies evaluating the 
algorithms’ effect on clinical outcome and health care burden in routine clinical care are 
scarce. A reliable algorithm for rapid rule-in and rule-out of ACS would enhance assessment 
of chest pain patients in the ED, enabling an early initiation of treatment for ACS, as well as 
an early discharge of patients in whom ACS has been ruled out. This would be of great value 
for the patients and would also optimize the utilization of the health care resources.  
The aim of this thesis was to add substantial knowledge to the research field by evaluating 
different assessment methods in patients presenting with symptoms suggestive of ACS, 
including a rapid rule-in and rule out algorithm for ACS recently implemented in routine 
clinical care. 
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2 INTRODUCTION 
 
2.1 ACUTE CORONARY SYNDROME 
 
ACS is the acute manifestation of coronary artery disease (CAD) and associated with a high 
morbidity and mortality. It is a major cause of death among both men and women in 
industrialized countries
17 18
. ACS is divided into the following three categories: 
1. UAP, defined as new onset or prompt worsening of previous stable angina pectoris, 
with symptoms at a low exertion level or at rest, but without any alteration in cardiac 
biomarker levels
3
.  
2. Non-ST-segment elevation MI (NSTEMI), defined as an MI without persistent ST-
segment elevations on electrocardiogram (ECG) 
3
. 
3. ST-segment elevation MI (STEMI), defined as an MI with persistent ST-segment 
elevations >20 minutes
3
. 
 
2.2 MYOCARDIAL INFARCTION DIAGNOSTICS 
 
2.2.1 Definition of myocardial infarction 
In 2000, the European Society of Cardiology (ESC) and the American College of Cardiology 
(ACC) published a consensus document regarding the definition of MI
19
. Until then, the 
official definition had been the 1979 World Health Organization (WHO) definition, in which 
MI criteria were considered to have been met in the presence of two out of three of the 
following: ischemic symptoms (i.e. chest pain or other symptoms suggestive of ACS), 
elevated cardiac biomarkers and ischemic ECG findings
20
. In spite of the WHO document, 
the MI definition varied between and even within countries
21
. The consensus document 
presented in 2000 aimed to state a universal definition of MI. Due to advances in the 
biomarker area, an alteration of cardiac biomarker levels, preferably cardiac troponin levels, 
was now made mandatory for an MI diagnosis in routine clinical care
19
.  
The consensus document has been successively updated
22-24
. Since the 2012 version, MI has 
been categorized into five different subtypes
23
:  
Type 1: Spontaneous MI caused by plaque rupture or erosion with non-occlusive or occlusive 
thrombus. 
Type 2: MI caused by an ischemic imbalance. 
Type 3: Sudden death with symptoms suggestive of MI but no biomarkers available. 
 4 
Type 4: Percutaneous coronary intervention (PCI)-related MI or MI due to stent thrombosis. 
Type 5: Coronary artery bypass grafting (CABG)-related MI. 
The current universal definition of MI dates from 2018 and includes a dynamic change in 
cardiac troponin, with at least one value above the 99
th
 percentile of healthy controls’ upper 
reference limit (URL). This must be combined either with ischemic symptoms, new ischemic 
ECG findings, new pathological Q-waves,  imaging evidence indicating recent or ongoing 
ischemia or identification of an intracoronary thrombus
22
. 
 
2.2.2 Troponins as cardiac biomarkers 
Cardiac troponins as biomarkers for MI were first presented at the end of the 1980s and 
introduced into routine clinical care two decades ago
25-29
. Due to their cardiac specificity and 
high sensitivity to cardiomyocyte injury, they have thereafter successively replaced other MI 
biomarkers such as creatine kinase MB (CK-MB), creatine kinase (CK) and myoglobin
19 30-33
. 
Troponins regulate the contraction process of striated muscle (i.e. skeletal and heart muscle). 
Three subunits of troponin have been identified, troponin C, I and T. Together they form a 
complex that attaches to the actin filaments in the myocyte, thus initiating the calcium 
dependent muscle contraction
32 34
. A small part of the troponin subunits also appears free in 
the cell cytosol
32
. Troponin I and T exist in cardiac isoforms, and are considered to be heart 
muscle-specific, whereas troponin C presents both in skeletal and heart muscle tissue 
32
. 
Elevated serum levels of troponin I and T indicate cardiomyocyte injury, and their detection 
and quantification is used in MI diagnostics
25 26
. Analyses are made by immunoassays, either 
run on automated platforms or by point-of-care tests. Automated platforms are recommended 
over point-of-care tests due to their higher sensitivity, greater diagnostic accuracy and greater 
negative predictive value (NPV)
3
.  However, point-of-care tests have a shorter turnaround 
time
3
. 
Even though elevated troponin levels are considered to be specific for cardiomyocyte injury, 
they are not specific for MI
35
. There are several other conditions in which elevated troponin 
levels, as well as dynamic changes in troponin, can be seen
36-38
. Such conditions, are, for 
example myocarditis, tachyarrhythmia, pulmonary embolism, decompensated heart failure 
and severe infections. 
 
2.2.3 High-sensitivity cardiac troponin assays 
Due to progress in technology in the biomarker area, the sensitivity of cardiac troponin assays 
has increased successively
39
. Since 2010, a new generation of troponin assays, called hs-cTn 
assays, has been marketed and is available in routine clinical care. Due to a greater precision 
in the lower measurement range, with results in the single digit range of nanograms per litre 
(ng/L) and a coefficient of variation of <10% below the 99
th
 percentile of healthy controls, 
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they should by definition have the capacity to detect cardiac troponin in >50% of healthy 
individuals
3 12 37 40
. Until recently, there have been two cardiac troponin assays labelled high-
sensitive available on the market, the Elecsys high-sensitivity cardiac troponin T (hs-cTnT) 
assay (Roche Diagnostics, Basel, Switzerland) and the ARCHITECT STAT high-sensitivity 
cardiac troponin I (hs-cTnI) assay (Abbott Laboratories, Chicago, IL, USA), even though the 
hs-cTnT assay does not meet the criterion of detection of cardiac troponin in >50% of healthy 
individuals
41
. The Elecsys hs-cTnT assay has a limit of detection (LoD) of 5 ng/L and a 99
th
 
percentile of healthy controls of 14 ng/L
12
. The ARCHITECT STAT hs-cTnI assay has an 
LoD of 1.2 to 1.9 ng/L
42 43
. According to the manufacturer, the single and sex-specific 
(men/women) 99
th
 percentiles of healthy controls are 26 ng/L and 34.2 /15.6 ng/L 
respectively. The assays are run on automated platforms. So far, there are no point-of-care 
tests fulfilling the criteria of a high-sensitivity assay. Studies have shown that the levels of hs-
cTn are generally higher in men than in women, and it has been suggested that a single hs-
cTn cut-off for men and women might lead to an under diagnosis of MI, especially among 
women 
43-47
. However, the available data are not concordant regarding the benefit of using 
sex-specific cut-offs for hs-cTnT or hs-cTnI
48-51
. 
Due to a low threshold of detection and a greater precision in the lower range of values, the 
hs-cTn assays have made early testing more reliable, and an elevation of hs-cTnT due to MI 
might be seen as early as within the first hour from symptom onset
3 52 53
. The high-sensitivity 
assays have also enabled identification of small changes in troponin during serial testing. The 
diagnostic accuracy of the available hs-cTnT and hs-cTnI assays is considered comparable
52
.  
The improved sensitivity of the troponin assays has at the same time resulted in a lower 
specificity for MI. Some patients who would be ruled out of MI with a conventional, non-
high-sensitive assay are now identified as patients with a cardiomyocyte injury, even though 
not all of these patient have an ongoing MI
22 39
. The decision to use the 99
th
 percentile of 
healthy controls as the cut-off for a non-pathological hs-cTn value has also led to an 
increased number of patients with a detected cardiomyocyte injury, since this cut-off is 
considerably lower than prior cut-offs used for MI diagnostics 
12 23 54
. Differentiation between 
a cardiomyocyte injury and an acute MI can be difficult, and a careful clinical examination is 
needed in order to distinguish between the two
22
. 
A recently published large Scottish study showed that the implementation of hs-cTnI 
combined with the use of the 99
th
 percentile as cut-off led to a reclassification of 17% of the 
patients presenting with symptoms suggestive of ACS. However, only one in three of these 
patients who had a cardiomyocyte injury detected with hs-cTnI but not with a conventional 
assay, had a final diagnosis of type 1 MI
55
. Furthermore, no difference in subsequent MI or 
cardiovascular death during one-year follow-up was seen between patients analysed with hs-
cTn and a conventional assay. The effect of implementing hs-cTnT in routine clinical care 
has also been evaluated in a large Swedish registry study. Hs-cTnT was found to increase the 
ability to adequately identify ACS patients, without admitting a larger number of patients 
without a final diagnosis of ACS
56
. A second large Swedish registry study showed that the 
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incidence of MI increased after the introduction of hs-cTn, while the risk of reinfarction 
decreased during follow-up
57
. A fourth study showed that patients diagnosed with non-
specific chest pain after evaluation with hs-cTnT in the ED, experienced fewer MACEs after 
discharge when compared to patients evaluated with a conventional assay 
8
. 
 
2.3 TRADITIONAL ASSESSMENT OF PATIENTS WITH SYMPTOMS 
SUGGESTIVE OF ACUTE CORONARY SYNDROME 
 
2.3.1 Measurement of troponin  
The introduction of cardiac troponins two decades ago facilitated the assessment of patients 
presenting to the ED with symptoms suggestive of ACS. Nevertheless, patients with acute 
symptom onset were to a great extent admitted to chest pain units in order to verify or rule 
out an ongoing ACS 
58
. In the 2007 ESC guidelines for the diagnosis and treatment of non-
ST-segment elevation ACS, an additional measurement of troponin was recommended 6 to 
12 hours after admission and again after 6 to 12 hours in case of recurrent pain after 
admission
59
. Omitting the 12-hour sample was considered safe only if the episode of chest 
pain occurred more than 12 hours before the baseline sample. Continuous ST-segment 
monitoring was recommended during the hospital stay.  
The 2011 ESC guidelines for the management of ACS in patients presenting without 
persistent ST-segment elevation presented a quicker way of ruling out MI for centres using 
hs-cTn assays
17
. In patients with hs-cTn results within the normal reference range 6 hours 
after symptom onset, further sampling was no longer required to rule out MI. In patients 
presenting within 6 hours from onset of symptoms who had a baseline hs-cTn below the 
upper limit of normal (ULN), a second hs-cTn was recommended 3 hours later. In case of a 
second value below the ULN, MI could be ruled out. These assessment strategies required a 
careful clinical examination and assessment of the patients’ symptoms and medical history. 
 
2.3.2 Risk scores 
In order to improve the clinical assessment of chest pain patients in the ED, the value of risk 
scores has been evaluated. The most frequently recommended scores have been the Global 
Registry of Acute Coronary Events (GRACE) and Thrombolysis in Myocardial Infarction 
(TIMI) scores. The GRACE score is developed in patients presenting with an ongoing ACS 
and estimates in-hospital and 6-month mortality
60
. It is based on findings at admission and 
includes the variables of age, heart rate, systolic blood pressure, creatinine, Killip class, 
cardiac arrest at admission, ST-segment deviation on ECG and elevated cardiac biomarkers. 
The calculation of the score is computerized. Likewise, the TIMI score is developed in an 
ACS population and predicts 14-day MACE and 14-day mortality 
61
. The score variables 
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collected at admission are age ≥ 65 years, ≥ three risk factors for CAD, prior coronary 
stenosis of 50% or more, ST-segment deviation on ECG, at least two episodes of angina 
pectoris within the last 24 hours, the use of aspirin over the last 7 days and elevated cardiac 
biomarkers. The score can be calculated manually, which is an advantage over the GRACE 
score. Several studies have compared the discriminative power of the two scores, but the 
results differ. While some studies found a superiority in discriminative power for the GRACE 
score
62 63
, other studies found the opposite
64 65
, and some study results indicate that the two 
scores are comparable
4
. The scores were developed in ACS populations, but the use of the 
scores is still recommended so as to facilitate the assessment of chest pain patients in the ED, 
a population at a much lower risk than the ACS populations
3 17 65-68
. 
 
2.3.3 Predischarge exercise ECG testing 
Patients admitted to a chest pain unit in whom MI has been ruled out by means of serial 
measurement of cardiac biomarkers and ECG, have traditionally been recommended stress 
testing before discharge. Exercise ECG testing has been the most widely used method due to 
its simplicity to perform, low complication rate and high NPV
17 59 69-73
. At Södersjukhuset 
Hospital, Stockholm, Sweden, almost a thousand patients admitted to the Department of 
Cardiology with chest pain during the 18 months 2011–2012 performed a predischarge 
exercise ECG test in order for the physicians to verify or rule out exercise-induced 
ischemia
74
. Several studies of exercise testing have been performed during the last decades, 
the largest including about one thousand patients each
70 71
. Even though there is a slight 
variation in patient selection between the studies evaluating predischarge exercise ECG 
testing in chest pain patients, they have shown similar results. About two thirds of the patients 
have a negative test result (i.e. normal), between zero and 30% a positive test result (i.e. 
findings indicating ischemia) and the rest an inconclusive test result
69 70
. The sensitivity of the 
test is limited to about 45–50%69 72 75. The NPV is high, which has been a strong argument for 
the use of the test
69 72
. The incidence of MI and death during follow-up is low, indicating that 
the populations investigated are low-risk
70 73 76 77
. More recent studies indicate that exercise 
ECG testing is less useful, due to an uncertain additional value in low-risk populations and a 
high proportion of inconclusive and false positive test results, which might lead to further 
redundant non-invasive and invasive testing
77 78
. Imaging stress tests, such as myocardial 
scintigraphy and stress echocardiography, are preferred due to their higher sensitivity, but 
these tests are not available at all centres
3 72
. 
Previous studies have indicated that exercise ECG testing has a lower sensitivity and 
specificity in women than in men
79
. Exercise-induced ST-segment depressions can occur in 
middle-aged women without CAD, which has been thought to be due to oestrogen levels
80
. In 
a study evaluating the prognostic value of exercise ECG testing in women after 
hospitalization for ACS at the beginning of the revascularization era, isolated exercise-
induced chest pain or isolated exercise-induced ST-segment depressions could not predict a 
recurrent event
81
. However, in other studies, ST-segment depressions during exercise ECG 
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testing performed shortly after an ACS were shown to be predictive of a recurrent event
82 83
. 
Evaluation of chest pain populations with exercise ECG testing has so far been recommended 
in both men and women
72
. 
 
2.4 NEW ALGORITHMS FOR ASSESSMENT OF PATIENTS WITH SYMPTOMS 
SUGGESTIVE OF ACUTE CORONARY SYNDROME 
 
2.4.1 Early rule-out of myocardial infarction in the emergency department 
In recent years, studies have questioned the need for admission and further testing in chest 
pain patients in whom MI has been ruled out in the ED
78 84
. These patients seem to have a 
very low risk of a future MACE or death, regardless of whether or not they are admitted for 
further non-invasive or invasive testing. If it were possible to safely rule out MI in the ED and 
to omit routine admission and further testing, this would have a great impact on routine 
clinical care.  
The high diagnostic and prognostic performances of the hs-cTn assays seem to have made the 
admission and further testing pathway unnecessary in many cases
56 85
. However, due to the 
2011 ESC guidelines recommending 6 hours between chest pain onset and analysis of hs-
cTn, or a second sample 3 hours after presentation in patients with a baseline hs-cTn result 
within the normal reference range to rule out MI, a majority of the chest pain patients have 
still been admitted in order to avoid a prolonged stay in the ED and new, more rapid 
algorithms are needed
17
.  
The hs-cTn assays have enabled more rapid assessment strategies due to the possibility of 
detecting small changes in troponin in the lower measurement range, thus offering the 
possibility of earlier testing
12
. The ambition is to radically shorten the time from presentation 
to diagnosis, while maintaining high patient safety. Several new rapid rule-in and rule-out 
troponin algorithms have been presented, of which those of most importance for this thesis 
will be presented here. 
 
2.4.2 Rule-out using an undetectable level of high-sensitivity cardiac 
troponin at presentation 
Body et al. suggested a rule-out algorithm based on a single hs-cTnT value at presentation
10
. 
The algorithm was first presented in 2011 and validated in a prospective observational study 
in 2016
11
. The study hypothesis was that a hs-cTnT below the LoD (i.e. hs-cTnT <5 ng/L) at 
presentation ruled out an ongoing MI. The 2016 study by Body et al. was a prospective 
multicentre study including 1,282 patients with symptoms suggestive of ACS presenting to 
the ED within 6 hours from symptom onset
11
. The primary outcome was MI at presentation, 
and patients were followed for 30 days regarding a MACE. A total of 560 patients had a hs-
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cTnT of <5 ng/L at presentation. Four of these patients (0.7%) were diagnosed with an MI at 
presentation which resulted in a sensitivity of the algorithm of 98.1% (95% confidence 
interval [CI] 95.3%–99.5%) and an NPV of 99.3 (95% CI 98.2%–99.8%). In order to 
improve the algorithm, ECG findings were added. In 471 patients with a hs-cTnT <5 ng/L 
and an ECG without ischemic findings, two (0.4%) had an MI. This resulted in a sensitivity 
of 99.1% (95% CI 96.7%–99.9%) and an NPV of 99.6% (95% CI 98.5%–100.0%). 
Altogether 36.7% of the patients in the study could be ruled out of MI at presentation, using 
the algorithm. These findings have been validated by several other research groups, using hs-
cTnT as well as hs-cTnI
86-92
.  
A short time delay between symptom onset and presentation lowers the sensitivity of the 
algorithm and increases the risk of missing MI patients however
11 89 90 92
. So far, the number 
of early presenters evaluated with this algorithm has been modest. It has been suggested that 
patients presenting with an undetectable level of hs-cTn who develop an MI are at a low 
overall risk, but there is little data to support that
86
. Moreover, mainly patients without a final 
diagnosis of MI have been included in the previous studies, and data on early presenting MI 
patients evaluated by this algorithm is limited
93
. 
 
2.4.3 Rule-in and rule-out using a one-hour high-sensitivity cardiac troponin 
algorithm 
A one-hour hs-cTnT algorithm to rule in or out an ongoing MI was presented by Reichlin et 
al. in 2012
14
. In the study, 872 patients with symptoms suggestive of MI within the last 12 
hours were included prospectively. Blood samples for analysis of hs-cTnT were taken at 
presentation and after one hour and analysed in a blinded fashion. All patients were followed 
for 30 days regarding a MACE. Patients with STEMI were excluded, since the diagnosis is 
not based on biomarkers. A total of 436 of the patients included were randomly selected to an 
algorithm derivation cohort. The algorithm was based on hs-cTnT at presentation and the 
absolute change in hs-cTnT levels (Δ hs-cTnT) within one hour. The rule-out thresholds were 
set to allow a 100% sensitivity and NPV for MI. The rule-in thresholds were set using a 
classification and regression tree (CART) analysis to optimize the rule-in part of the 
algorithm. The derivation of the algorithm resulted in the following pathways: (1) rule-out if 
hs-cTnT at presentation <12 ng/L and Δ hs-cTnT<3 ng/L, (2) rule-in if hs-cTnT at 
presentation ≥52 ng/L or Δ hs-cTnT ≥5 or (3) an observational zone for the remaining 
patients. The derived algorithm was then validated in the remaining 436 patients included, 
and the result was as follows: a total of 259 patients (59.4%) were ruled out of MI after one 
hour, with a sensitivity of 100% and an NPV of 100%. A total of 76 patients were ruled in 
with the algorithm. Out of these, 64 had a final diagnosis of MI and the specificity and the 
positive predictive value (PPV) of the algorithm was 97% and 84% respectively. The 
observational zone included 101 patients, of whom 8 had a final diagnosis of MI. Altogether, 
a final diagnosis could be set after one hour in 77% of the patients in the validation cohort.  
 10 
The diagnostic and prognostic performances of the one-hour hs-cTnT algorithm have been 
evaluated in several prospective observational studies and algorithm thresholds for hs-cTnI 
have been derived and validated
13 94-98
. In these studies, the sensitivity and NPV for the rule-
out cohort has been slightly lower than the 100% set up in the original study. However, data 
regarding implementation and performance of the algorithm in routine clinical care are 
lacking, and results may differ when applied to an unselected ED population of chest pain 
patients. 
 
2.4.4 New guidelines recommending the use of rapid rule-in and rule-out 
algorithms 
In 2015, the current ESC guidelines for the management of ACS in patients presenting 
without persistent ST-segment elevation were published
3
. As a complement to the assessment 
strategy presented in 2011, the algorithm using undetectable levels of troponin at presentation 
and the one-hour troponin algorithm described above were recommended as an alternative in 
the presence of hs-cTn assays. Due to limited data and inferior performance among early 
presenters as discussed above, the ESC guidelines recommend at least 3 hours between 
symptom onset and analysis of hs-cTn in order to apply the algorithms
3
. In addition, the 
algorithms are recommended together with a detailed assessment of symptoms and ECG
3
. 
 
2.4.5 Clinical assessment using the HEART score 
Using a risk score is a structured way to clinically assess patients. The History, ECG, Age, 
Risk factors and Troponin (HEART) score was presented by Six et al. in 2008 and is a risk 
score developed to assess the risk of an acute MACE in chest pain patients presenting to the 
ED
65
 
99 100
. It comprises the five variables of history, ECG, age, risk factors of atherosclerotic 
disease and troponin. Each variable is rated between zero and two points. The minimum total 
score is zero points and the maximum is ten points (Table 1). A HEART score of 0–3 points 
is categorized as a low risk of a MACE, while a score of 4–6 points as an intermediate risk 
and a score of 7–10 as a high risk5 60 99 101-103. The HEART score is developed and validated 
in a low-risk population of chest pain patients in the ED, in contrast to the  GRACE and the 
TIMI scores which are developed and evaluated in ACS populations
60 61 101 102
. 
The HEART score has been validated by Backus et al. in both a retrospective and a 
prospective multicentre validation
101 102
. The prospective study presented in 2013 included 
2,388 chest pain patients who were followed for 6 weeks after presentation in the ED
101
. A 
total of 36.4% of the study population was categorized as low-risk according to the HEART 
score result and 1.7% of these patients experienced a MACE within follow-up, compared to 
16.6% of the patients in the intermediate risk group and 50.1% of the patients in the high-risk 
group. Similar results were found in a prospective multicentre validation by Poldervaart et al. 
in 2017
65
. A total of 40.5% of the 1,748 chest pain patients included in this prospective study 
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had a HEART score of 0–3 points, and 2.0% of these patients experienced a MACE within 6 
weeks of follow-up. 
 
Table 1. The HEART score. 
History Highly suspicious  2 
Moderately suspicious 1 
Slightly suspicious 0 
ECG Significant ST-segment depression 2 
Non-specific repolarization disturbance 1 
Normal 0 
Age  ≥65 years 2 
45–64 years 1 
<45 years 0 
Risk factors ≥3 risk factors or history of atherosclerotic disease 2 
1 or 2 risk factors 1 
No risk factors known 0 
Troponin ≥ 3 x ULN 2 
>1–<3 x ULN 1 
≤ ULN 0 
ECG, electrocardiogram; ULN, upper limit of normal. 
 
The HEART score has also been evaluated retrospectively in a Swedish population
5
. In 410 
Swedish chest pain patients, 247 (60.2%) had a HEART score of 0–3 points and of these one 
patient (0.4%) experienced a MACE within three months of follow-up
5
. Hence, a 
considerable proportion of the chest pain population in the ED seem to have a HEART score 
of 0–3 points, which is associated with a very low risk of an acute MACE. 
Comparisons of the HEART, GRACE and TIMI scores have been performed. The HEART 
score has been shown to have at least as good precision as the TIMI score and better precision 
than the GRACE score in identifying low-risk patients, with a higher proportion of patients 
classified as low-risk patients, but the results vary somewhat between studies
4 64 65 104
. In a 
recent study, the HEART score was superior in discriminating for a MACE when compared 
to the other scores
65
. The HEART score has also been compared to exercise ECG testing in 
chest pain patients presenting to the ED. In a small prospective study (n=248), no significant 
additive value of exercise ECG testing could be shown in patients who had already been 
assessed using the HEART score 
77
. 
These data support the use of the HEART score in routine clinical care. However, when 
implemented as a rule-in and rule-out algorithm in a large stepped-wedge, cluster-randomized 
trial, the assessment strategy was shown to be safe, but no significant effect on utilization of 
health care resources was seen
103
. This was thought to be due to nonadherence to the HEART 
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score algorithm and might be explained by the fact that clinicians did not rely on a rule-out 
strategy that only included a risk score. Moreover, in a recent meta-analysis, 3.3% of patients 
with a HEART score of 0–3 points experienced a MACE during follow-up105. 
 
2.4.6 Rapid rule-in and rule-out algorithms evaluated in routine clinical care 
While the rapid hs-cTn algorithms described in Chapters 2.4.2 and 2.4.3 have not yet been 
evaluated in routine clinical care, several other new algorithms in addition to the HEART 
score algorithm have. The algorithms of importance for this thesis will be presented here. 
However, even though they have been evaluated in routine clinical care and compared in 
reviews, direct comparisons between these algorithms are lacking
106
. 
2.4.6.1 Troponin combined with copeptin 
In a large multicentre randomized controlled trial (RCT) presented in 2014, Möckel et al. 
compared the combination of a single measurement of troponin and copeptin at presentation 
with the rule-out strategy presented in the 2011 ESC guidelines
107
. Copeptin is a marker of 
acute stress that has been shown to rise promptly in MI patients
108
. The combination was 
shown to be as safe as the traditional strategy but, when using hs-cTn assays instead of 
conventional troponin assays, copeptin did not provide any additional diagnostic 
information
107 109
. 
2.4.6.2 A two-hour hs-cTn I algorithm combined with the TIMI score 
An algorithm based on measurement of hs-cTnI at presentation and after two hours combined 
with a modified TIMI score was evaluated in a single-centre randomized, parallel-group trial 
by Than et al. in 2014
110
. To classify a patient as low risk according to the modified TIMI 
score, all variables of the score had to be negative. The two-hour algorithm was compared to 
a traditional assessment strategy that included measurement of hs-cTn 6–12 h after symptom 
onset and often included admission. It showed that 19.3 % of patients in the two-hour 
algorithm group, compared to 11.0% in the traditional assessment group, were discharged 
within 6 hours and without experiencing a MACE within 30 days of follow-up. 
2.4.6.3 The HEART pathway 
In this small single-centre RCT (n=282) by Mahler et al. presented in 2015, patients 
evaluated with a three-hour algorithm using conventional troponin combined with the 
HEART score were compared to patients receiving standard care according to the 2007 
ACC/American Heart Association (AHA) guidelines recommending serial troponin 
measurement and objective cardiac testing before discharge
67 111
. With this new strategy, the 
admission rate decreased from 78% to 61% and the length of stay in the hospital was reduced 
from 21.9 to 9.9 hours, without any increase in MACE during the 30-day follow-up.  
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In a small multicentre RCT (n=105) by Frisoli et al. presented in 2017, patients ruled-out of 
MI by the HEART pathway were randomized either to a direct discharge from the ED, or to 
non-invasive stress testing
112
. By using the HEART pathway, the length of stay was reduced 
from 25.9 to 6.3 hours and the total costs from $9,616 to $2,950. No MACE occurred in any 
of the groups during the 30-day follow-up. 
2.4.6.4 The EDACS accelerated diagnostic pathway 
In a single-centre RCT by Than et al., the newly developed and validated Emergency 
Department Assessment of Chest Pain Score (EDACS) was compared to the modified TIMI 
score
6 110 113
. The EDACS was developed to be applied in an unselected chest pain population 
in the ED and includes the variables of age, sex, risk factors for CAD or established CAD, 
and symptom characteristics. Patients in both groups were assessed according to routine 
clinical care including measurement of hs-cTnI at presentation and after two hours. There 
was no difference in the proportion of patients who were discharged within 6 hours and 
without experiencing a MACE within 30 days of follow-up (32.3% in the EDACS group vs. 
34.4% in the modified TIMI score group), indicating that the EDACS could be implemented 
in routine clinical care. The same research group recently showed that the implementation of 
such accelerated diagnostic pathways in routine clinical care increases the number of early 
discharged patients and with very low risk
114
. 
2.4.6.5 Shared decision making in the ED 
In this large multicentre RCT by Hess et al., standard care was compared to shared decision 
making where patients were informed of their calculated risk of ACS and, together with the 
physician, decided whether they should be admitted for further testing or discharged and 
followed-up in an outpatient setting
115
. The admission rate decreased from 52.1% among 
patients assessed according to standard care to 37.3% among patients in the shared decision-
making group. The proportion of patients who underwent stress testing within 30 days 
decreased from 45.6% to 38.1%. None of the patients who were directly discharged from the 
ED experienced a MACE within 30 days. 
2.4.6.6 The MACS decision rule 
In a small, single-centre pilot RCT (n=138) by Body et al. presented in 2017, patients 
assessed according to the Manchester Acute Coronary Syndromes (MACS) decision rule 
were compared to patients receiving standard care
116
. The MACS decision rule is based on 
measurement of hs-cTnT, heart type fatty acid binding protein and blood pressure at 
presentation combined with ECG findings and symptom characteristics. A total of 26% of the 
patients assessed according to the MACS decision rule were discharged within 4 hours, 
compared to 8% of the patients in the standard care group. None of these patients experienced 
a MACE within 30 days. 
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2.5 MEASUREMENTS OF DIAGNOSTIC TESTS 
 
Measurements of diagnostic tests are discussed throughout this thesis. To facilitate reading, 
they are briefly explained here. 
 
2.5.1 Sensitivity 
Sensitivity is the proportion of individuals with a certain disease that are correctly identified 
by a pathologic diagnostic test (e.g. an MI patient identified by an elevated troponin level)
117
. 
The sensitivity should be high in diagnostic tests where the aim is not to miss any individuals 
with the disease. Sensitivity is not affected by the prevalence of the disease. 
 
2.5.2 Specificity 
Specificity is the proportion of individuals without a certain disease that are correctly 
identified by a non-pathologic diagnostic test (e.g. a chest pain patient without MI who turns 
out to have a non-elevated troponin level)
117
. The specificity should be high in diagnostic 
tests where the aim is to detect a disease in a population. Specificity is not affected by the 
prevalence of the disease. 
 
2.5.3 Positive predictive value 
PPV is the proportion of individuals with a pathological test result that are correctly 
diagnosed (e.g. a patient with an elevated troponin who turns out to have an MI)
117
. PPV is 
affected by the prevalence of the disease. The higher the prevalence, the higher the PPV and 
in a population where the prevalence of a certain disease is high, the PPV of a diagnostic test 
will be high by default. 
 
2.5.4 Negative predictive value 
NPV is the proportion of individuals with a normal test result that are correctly diagnosed 
(e.g. a patient with a non-elevated troponin and without an MI)
117
. NPV is affected by the 
prevalence of the disease. The lower the prevalence, the lower the NPV and in a population 
where the prevalence of a certain disease is low, the NPV of a diagnostic test will be low by 
default. 
 
  15 
2.5.5 Efficacy vs. safety 
When choosing a rule-in and rule-out algorithm to implement in routine clinical care, there is 
a trade-off between efficacy (i.e. the algorithm’s capacity to classify patients as rule-in or 
rule-out) and safety (i.e. the algorithm’s capacity to correctly rule out patients). Using a hs-
cTn algorithm alone seems to improve the efficacy compared to a combined hs-cTn and risk 
score algorithm while the latter seems to improve the safety
118
. Increased safety could 
increase the clinicians’ adherence rate. In addition, a hs-cTnT algorithm cannot identify UAP 
patients while combined algorithms might. There is no general recommendation for the 
sensitivity for ACS or MI of a rule-in and rule-out algorithm, but it seems impossible to 
obtain a sensitivity of 100% in routine clinical care without admitting all presenting patients. 
However, redundant admittance of patients is not always good for the patients and also leads 
to an ineffective utilization of health care resources. In routine clinical care, a sensitivity at or 
above 99% is often the aim among clinicians. In a survey performed among1,029 ED 
physicians in New Zealand, Australia, USA and Canada, about 40% of the participants were 
willing to accept a miss-rate of a MACE of 1% and 55% a miss-rate of 0.5%
119
.  
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3 AIMS 
 
The overall aim of this thesis was to evaluate four methods of assessing patients presenting 
with symptoms suggestive of ACS in the era of hs-cTn, including a new assessment strategy 
for these patients recently implemented in routine clinical care in Stockholm and Uppsala, 
Sweden. 
The specific aims of the individual studies were: 
Study I To evaluate the value of predischarge exercise ECG testing in chest pain 
patients in whom MI had been ruled out by means of hs-cTnT. 
Study II To evaluate the diagnostic sensitivity of using an undetectable level of hs-cTnT 
at presentation, with and without information from the ECG, in order to rule out 
MI in a NSTEMI population presenting early after onset of symptoms. 
Study III To evaluate the use of a one-hour measurement of hs-cTnT in routine clinical 
care in an ED population of chest pain patients with a non-elevated hs-cTnT at 
presentation and to examine early dynamic changes in hs-cTnT. 
Study IV To evaluate whether the clinical implementation of a one-hour hs-cTnT or I 
algorithm combined with the HEART score would reduce admission rates and 
affect the time to discharge, health care-related costs and outcome. 
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4 METHODS 
 
4.1 ETHICAL CONSIDERATIONS 
 
The studies were conducted according to the principles of the Declaration of Helsinki
120
 and 
approved by the Regional Ethical Review Board in Stockholm (Study I approval number 
2013/841-31/2, Study II approval number 2017-331/31, Study III approval number 2016/744-
31/4 and Study IV approval number 2013/621-31/4).  
Study I–III were retrospective studies, and the possible harm for the participating patients 
was considered to be negligible. 
Study IV was a prospective observational study conducted according to Good Clinical 
Practice Guidelines
121
, and written informed consent was obtained from all participants. The 
patients participating received the same clinical assessment as patients outside the study. 
Additional blood samples were taken from the participants, both for instant analysis and for 
bio banking. Blood sampling may lead to complications such as bleeding, haematomas or 
infections, but these complications are very rare. The amount of blood obtained could not 
lead to anaemia. 
The data used were made anonymous before analysis and presentation in all studies and could 
not be connected to specific patients. The aim was to design clinically relevant studies with 
adequate research questions. It would then be possible for the patients participating in the 
studies to benefit from the study results in the future. If the studies improved the assessment 
of patients presenting with symptoms suggestive of ACS, the positive effect would outweigh 
the minimal risks that the participating patients were exposed to. 
 
4.2 STUDY I 
 
4.2.1 Study design, setting and participants 
In this retrospective study, all patients who underwent predischarge exercise ECG testing 
while admitted to the Department of Cardiology, Södersjukhuset Hospital, Stockholm, 
Sweden from January 1, 2011 to June 30, 2012 were screened for inclusion. Consecutive 
patients admitted due to symptoms suggestive of ACS in whom MI had been ruled out by 
means of hs-cTnT before the exercise ECG test were included if they had a Swedish identity 
number and were registered in the County of Stockholm from the inclusion date to the end of 
the follow-up. Patients could only be included once in the study. 
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4.2.2 Data sources and variables 
Baseline and presentation characteristics and exercise ECG test data were retrieved from the 
hospital’s medical records. All baseline ECGs were assessed. The exercise ECG test data 
were assessed and categorized as negative (i.e. normal), positive (i.e. pathological) or 
inconclusive. If no classification could be made based on the given data, the continuous 
ECG-registration was reviewed. Follow-up data were retrieved from the hospital’s medical 
records, the Swedish web-system for enhancement and development of evidence-based care 
in heart disease evaluated according to recommended therapies (SWEDEHEART) registry
122
 
and the Public Healthcare Services Committee Administration of the Stockholm County 
Council. All diagnoses were coded according to the International Classification of Diseases 
(ICD-10)
123
. Study endpoints were death, MI, death and MI combined and post-discharge 
revascularization within 90 and 365 days respectively. Data from Statistics Sweden and the 
National Board of Health and Welfare were used to calculate the one-year risk of death and 
MI in an age, gender and calendar time-matched Swedish population. 
 
4.2.3 Statistical methods  
Categorical variables were presented as numbers and percentages and continuous data as 
medians with interquartile ranges (IQR). The chi-square test or Fisher’s exact test were used 
to evaluate differences in proportions between the exercise ECG test outcome groups. The 
Mann-Whitney U test was used to compare continuous variables. All statistical analyses were 
performed using IBM SPSS Statistics version 22, Armonk, North Castle, NY, USA. 
 
4.3 STUDY II 
 
4.3.1 Study design, setting and participants 
This retrospective study was conducted after the introduction of hs-cTnT in the County of 
Stockholm, Sweden in December 2010. All patients admitted to five centres in Stockholm 
from January 1, 2011 to December 31, 2015 presenting ≤2 hours from symptom onset and 
receiving a final diagnosis of NSTEMI were identified through the SWEDEHEART registry. 
These inclusion criteria were verified in the hospitals’ medical records. Analysis of hs-cTnT 
at presentation was mandatory for inclusion, and patients with cardiac arrest prior to 
presentation, as well as patients with a prior participation in the study, were excluded. 
 
4.3.2 Data sources and variables 
Data regarding presentation, symptom onset, results of hs-cTnT measurements and NSTEMI 
diagnosis were retrieved from the hospitals’ medical records. All ECGs in patients presenting 
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with an undetectable level of hs-cTnT (i.e. <5 ng/L) were assessed. The SWEDEHEART 
registry provided all other baseline and outcome data. The diagnostic sensitivity for MI when 
using an undetectable level of hs-cTnT at presentation to rule out MI was calculated 
separately in patients presenting ≤2 hours, >1 hour to ≤2 hours and ≤1 hour from symptom 
onset. The additive value of a non-ischemic ECG was calculated. Patients aged ≤65 years 
without prior MI were analysed separately. NSTEMI patients with and without a detectable 
level of hs-cTnT at presentation were compared regarding baseline and in-hospital 
characteristics and revascularization and death at 30 days. 
 
4.3.3 Statistical methods  
Sensitivity for MI with the exact Clopper-Pearson 95% CI for the observed proportion was 
calculated. Categorical variables were given as numbers and percentages and continuous data 
as medians (IQR). The chi-square test or Fisher’s exact test were used to evaluate differences 
in proportions. The Mann-Whitney U test was used to compare continuous variables. All 
statistical analyses were performed using IBM SPSS Statistics version 23, Armonk, North 
Castle, NY, USA or MedCalc version 18.2.1, MedCalc Software, Ostend, Belgium. 
 
4.4 STUDY III 
 
4.4.1 Study design, setting and participants 
This retrospective study was conducted after the introduction of a new algorithm combining 
measurement of hs-cTn at presentation and after one hour with calculation of the HEART 
score in routine clinical care. The algorithm is described in Chapter 4.5.1. Screening for 
eligible patients was made through the Karolinska University Hospital Database (KARDA) 
which consists of data from the hospital’s medical records. All patients with a registered chief 
complaint of chest pain presenting to the ED of Karolinska University Hospital, Solna, 
Sweden, from December 1, 2014 to September 14, 2015 who had a Swedish identity number 
and two hs-cTnT measurements obtained during the ED visit with a time period between the 
first and second sample of >30–≤90 minutes were included. Patients with STEMI or 
ventricular tachycardia were excluded. Patients could only be included once, and one of the 
visits during the study period was randomly chosen. 
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4.4.2 Data sources and variables 
Baseline data were retrieved from the KARDA. Outcome data were retrieved from the 
KARDA with a linkage to the Swedish population register. All diagnoses were coded 
according to ICD-10
123
. In patients with a main diagnosis of MI, the diagnosis and MI type (1 
or 2) was adjudicated. All patients with a baseline hs-cTnT value of ≤14 ng/L were followed 
for 30 days regarding the following endpoints: admission, readmission, MI and death. 
Patients with a dynamic one-hour change in hs-cTnT (i.e. Δ3 ng/L) were compared to those 
with a non-dynamic change in hs-cTnT (i.e. Δ<3 ng/L). The HEART score was calculated 
retrospectively in the subgroup of patients with a dynamic one-hour change in hs-cTnT levels 
and in those with an ACS diagnosis but without a dynamic one-hour change in hs-cTnT. 
 
4.4.3 Statistical methods  
Categorical variables were presented as numbers and percentages. Continuous data were 
presented as mean with standard deviations or medians (IQR) or minimum and maximum 
(min– max) range as appropriate. The chi-square test or Fisher’s exact test were used to 
evaluate differences in proportions. Comparisons of continuous variables were made with the 
Student’s t-test for normally distributed variables and with the Mann-Whitney U-test for 
other continuous variables. All statistical analyses were performed using STATISTICA 
version 12 (2014) (Stat Soft Inc., Tulsa, OK, USA) and Microsoft Excel (Microsoft Office 
2008) (Microsoft Corp., Redmond, WA, USA). 
 
4.5 STUDY IV 
 
4.5.1 Study design, setting and participants 
The Fast ASsessment of Thoracic pain in the Emergency department using high-Sensitive 
Troponins and a simple risk score (FASTEST) study was a prospective observational study 
conducted at six centres in Stockholm and Uppsala, Sweden. The study was divided into two 
phases, before and after the implementation of a new algorithm for patients presenting to the 
ED with symptoms suggestive of ACS. During phase 1 (June 4, 2013– September 2, 2014), 
patients were assessed according to local guidelines based on recommendations from the ESC 
and ACC/AHA. During phase 2 (January 27, 2015– May 20, 2016), patients were assessed 
according to the new algorithm which applied a modified one-hour hs-cTn algorithm in 
combination with calculation of the HEART score (Figure 1). In patients with a baseline hs-
cTnT or I within the ULN, a one-hour change in hs-cTnT <3 ng/L or hs-cTnI <6 ng/L and a 
HEART score ≤3, ACS was considered unlikely. In patients with a baseline hs-cTnT or I 
within the ULN, a one-hour change below these cut-offs and a HEART score 4, MI was 
considered unlikely, but the risk of an ACS was considered elevated. In patients with a 
  23 
baseline hs-cTnT or I within the ULN, a one-hour change in hs-cTnT 3 or hs-cTnI 6 ng/L, 
an ongoing MI should be considered regardless of the HEART score. Inclusion criteria were 
symptoms suggestive of ACS, symptom duration of 10 minutes and onset of last episode 
≤12 hours. Patients presenting with ST-segment elevation or new left bundle branch block on 
ECG were excluded.  
 
 
Figure 1. The new algorithm. The new algorithm included measurement of hs-cTn at 
presentation and after one hour, combined with the HEART score. To be considered “low 
risk” hs-cTn needed to be within the normal reference range at baseline, i.e. the HEART-
score for troponin=0.”   
Hs-cTn levels are expressed in nanograms/litre. 
♂ indicates men; ♀ indicates women; Δ indicates delta; ED, emergency department; h, hour, hs-cTn; high-
sensitivity cardiac troponin; hs-cTnI, high-sensitivity cardiac troponin I; hs-cTnT, high-sensitivity cardiac 
troponin T; MI, myocardial infarction. 
 
4.5.2 Data sources and variables 
All data collection was performed by a research assistant who entered the data onto a web-
based case report form. Patients were followed by a telephone call at the end of a 30-day 
follow-up, and by the hospitals’ medical records if necessary. All study cases with an 
elevated troponin level during the index visit or readmission to hospital were adjudicated 
regarding whether or not the MI criteria were fulfilled
23
. The primary endpoint of the study 
was admission rate, defined as the rate of patients admitted to an in-patient ward. Secondary 
endpoints were time to discharge from the hospital, health care-related costs and clinical 
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outcomes defines as new presentation to the ED, readmission to the hospital, unplanned 
revascularization, MI or death. 
 
4.5.3 Statistical methods  
The power calculation for the primary endpoint was based on an expected admission rate of 
45% during phase 1 and 35% during phase 2. In order to detect a reduction in admission rate 
of 10% with a power of 0.90 and an alpha-value of 0.05, a total of 524 patients were required 
in each phase. Categorical variables were presented as numbers and percentages and 
continuous data as medians (IQR). The chi-square test or Fisher’s exact test were used to 
evaluate differences in proportions between phase 1 and 2 according to the intention-to-treat 
principle. The risk ratio (RR) with 95% CI was calculated. The Mann-Whitney U test was 
used to compare continuous variables. A logistic regression analysis was performed to adjust 
for differences in baseline characteristics between phase 1 and 2. A sensitivity analysis was 
performed in order to adjust for an index diagnosis of MI vs. non-MI. All statistical analyses 
were performed using IBM SPSS Statistics version 23, Armonk, North Castle, NY, USA. 
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5 RESULTS 
 
5.1 STUDY I 
 
5.1.1 Study population 
A total of 951 patients were included in the analysis. The median (IQR) age was 62 (51–70) 
years and 428 (45.0%) of the patients were women. The presentation ECG was normal in 658 
patients (69.2%). A total of 909 patients (95.6%) had more than one hs-cTnT sample taken 
during the hospital stay and 820 (86.2%) had a peak level of hs-cTnT ≤14 ng/L. In total, 111 
patients (11.7%) were initially treated for a suspected ACS, but the diagnosis was ruled out 
before the exercise ECG test. In 585 patients (61.5%), the exercise ECG test was negative, in 
94 (9.9%) positive and in 272 (28.6%) inconclusive. In comparison with patients with 
negative tests, patients with positive or inconclusive tests were older, more often male, had 
more risk factors, were more often being treated with beta-blockers and had more often a 
peak level of hs-cTnT >14 ng/L or a pathological ECG.  
 
5.1.2 Main findings 
Ninety-five patients (10.0%) underwent coronary angiography during their hospital stay 
(Table 2). A total of 46 (4.8%) patients were revascularized before discharge and an 
additional 39 (4.1%) during the one-year follow-up. Overall, there were 3 (0.3 %) and 9 (0.9 
%) deaths and 4 (0.4%) and 10 (1.1%) MIs within 90 and 365 days, respectively. In an age, 
gender and calendar time-matched Swedish population the one-year rate of death was 1.3% 
and the one-year rate of MI 0.5%.  
Patients with a positive exercise ECG test were more likely to undergo coronary angiography 
and subsequent PCI in hospital, as well as revascularization after discharge when compared 
to patients with a negative test (Table 2). There were no statistically significant differences 
regarding death or MI between patients with a positive or a negative test, neither at 90 (1.1% 
vs. 0.2%) nor at 365 days (2.1% vs. 0.7%) of follow-up. Patients with an inconclusive test 
had a worse prognosis than patients with a negative test and were more likely to reach the 
combined endpoint death or MI during follow-up. A total of 445 patients with a normal ECG 
at presentation and a hs-cTnT peak level of <5 ng/L were analysed separately. Only two 
deaths and one MI occurred in this cohort within 365 days of follow-up.  
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Table 2. Outcome at 90 and 365 days. Patients were divided into groups based on the 
predischarge exercise ECG test result. 
 n (%) 
 All patients 
(n=951) 
Negative 
exercise ECG 
test (n=585) 
Positive 
exercise ECG 
test (n=94) 
Inconclusive 
exercise ECG 
test (n=272) 
Coronary angiography before discharge 95 (10.0) 12 (2.1) 45 (47.9) *** 38 (14.0) *** 
Significant stenosis before discharge 51 (5.4) 4 (0.7) 29 (30.9) *** 18 (6.6) *** 
Revascularization before discharge 46 (4.8) 4 (0.7) 28 (29.8) *** 14 (5.1) *** 
Imaging stress test performed after discharge 
but before any coronary angiography 
154 (16.2) 58 (9.9) 23 (24.5) *** 73 (26.8) *** 
Positive imaging stress test 20/154 (13.0) 7/58 (12.1) 4/23 (17.4) 9/73 (12.3) 
Death due to any cause ≤90 days 3 (0.3) 1 (0.2) 0 (0.0) 2 (0.7) 
Myocardial infarction ≤90 days 4 (0.4) 0 (0.0) 1 (1.1) 3 (1.1) * 
Any revascularization after discharge ≤90 
days 
18 (1.9) 1 (0.2) 8 (8.5) *** 9 (3.3) *** 
Death or myocardial infarction ≤90 days 7 (0.7) 1 (0.2) 1 (1.1) 5 (1.8) * 
Other cardiovascular readmission ≤90 days 33 (3.5) 8 (1.4) 8 (8.5) ** 17 (6.3) *** 
Death due to any cause ≤365 days 9 (0.9) 2 (0.3) 0 (0.0) 7 (2.6) ** 
Myocardial infarction ≤365 days 10 (1.1) 2 (0.3) 2 (2.1) 6 (2.2) * 
Any revascularization after discharge ≤365 
days 
39 (4.1) 7 (1.2) 16 (17.0) *** 16 (5.9) *** 
Death or myocardial infarction ≤365 days 19 (2.0) 4 (0.7) 2 (2.1) 13 (4.8) *** 
Other cardiovascular readmission ≤365 days 87 (9.1) 28 (4.8) 20 (21.3) *** 39 (14.3) *** 
*=p<0.05, **=p<0.01, ***= p<0.001 when compared to patients with a negative exercise ECG test. 
ECG, electrocardiogram. 
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5.1.3 Gender differences 
The median (IQR) age among men and women was 60 (51–69) and 62 (53–70) years 
respectively and 170 (32.5%) of the men and 65 (15.2%) of the women had a history of 
ischemic heart disease. Men and women had to a similar extent a normal ECG at presentation 
(69.2% and 70.1% respectively). Altogether 281 (53.7%) of the men and 301 (70.3%) of the 
women had a maximum hs-cTnT <5 ng/L, and 157 (30.0%) of the men and 81 (18.9%) of the 
women had a maximum hs-cTnT of 5–14 ng/L. The exercise ECG test outcome in men was 
58.5% negative tests, 13.6% positive tests and 27.9% inconclusive tests (Table 3). Among 
women, 65.2% of the tests were negative, 5.4% positive and 29.4% inconclusive (Table 4). 
 
Table 3. Outcome at 90 and 365 days in men. Patients were divided into groups based on 
the predischarge exercise ECG test result. 
 n (%) 
 All patients 
(n=523) 
Negative 
exercise ECG 
test (n=306) 
Positive 
exercise ECG 
test (n=71) 
Inconclusive 
exercise ECG 
test (n=146) 
Coronary angiography before discharge 63 (12.0) 7 (2.3) 36 (50.7) *** 20 (13.7) *** 
Revascularization before discharge 33 (6.3) 3 (1.0) 23 (32.4) *** 7 (4.8) * 
Death due to any cause ≤ 90days 3 (0.6) 1 (0.3) 0 (0) 2 (1.4) 
Myocardial infarction ≤90 days 2 (0.4) 0 (0) 1 (1.4) 1 (0.7) 
Any revascularization after discharge 
≤90 days 
15 (2.9) 1 (0.3) 7 (9.9) *** 7 (4.8) ** 
Death or myocardial infarction ≤90 
days 
5 (1.0) 1 (0.3) 1 (1.4) 3 (2.1) 
Death due to any cause ≤365 days 7 (1.3) 2 (0.7) 0 (0) 5 (3.4)* 
Myocardial infarction ≤365 days 4 (0.8) 1 (0.3) 1 (1.4) 2 (1.4) 
Any revascularization after discharge 
≤365 days 
29 (5.5) 4 (1.3) 12 (16.9) *** 13 (8.9) *** 
Death or myocardial infarction ≤365 
days 
11 (2.1) 3 (1.0) 1 (1.4) 7 (4.8) * 
*=p<0.05, **=p<0.01, ***= p<0.001 when compared to patients with a negative exercise ECG test. 
ECG, electrocardiogram. 
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A total of 63 (12.0%) of the men underwent coronary angiography before discharge, and 33 
(6.3%) were revascularized, compared to 32 (7.5%) and 13 (3.0%) of the women (Table 3 
and 4). In men, there were overall 3 (0.6%) deaths and 2 (0.4%) MIs after 90 days and 7 
(1.3%) deaths and 4 (0.8%) MIs after 365 days of follow-up. In women, there were no deaths 
but 2 (0.5%) MIs after 90 days and 2 (0.5%) deaths and 6 (1.4%) MIs after 365 days of 
follow-up. None of the men or women with a positive exercise ECG test died during follow-
up and there was no statistically significant difference in the proportion of MIs between those 
with a positive and a negative exercise test. Both men and women with a positive exercise 
test were revascularized to a significantly greater extent during the 365-day follow-up when 
compared to those with a negative test. 
 
Table 4. Outcome at 90 and 365 days in women. Patients were divided into groups based 
on the predischarge exercise ECG test result. 
 n (%) 
 All patients 
(n=428) 
Negative 
exercise ECG 
test (n=279) 
Positive 
exercise ECG 
test (n=23) 
Inconclusive 
exercise ECG 
test (n=126) 
Coronary angiography before discharge 32 (7.5) 5 (1.8) 9 (39.1) *** 18 (14.3) *** 
Revascularization before discharge 13 (3.0) 1 (0.4) 5 (21.7) *** 7 (5.6) ** 
Death due to any cause ≤ 90days 0 (0) 0 (0) 0 (0) 0 (0) 
Myocardial infarction ≤90 days 2 (0.5) 0 (0) 0 (0) 2 (1.6) 
Any revascularization after discharge  
≤90 days 
3 (0.7) 0 (0) 1 (4.3) 2 (1.6) 
Death or myocardial infarction ≤90 days 2 (0.5) 0 (0) 0 (0) 2 (1.6) 
Death due to any cause ≤365 days 2 (0.5) 0 (0) 0 (0) 2 (1.6) 
Myocardial infarction ≤365 days 6 (1.4) 1 (0.4) 1 (4.3) 4 (3.2) * 
Any revascularization after discharge 
≤365 days 
10 (2.3) 3 (1.1) 4 (17.4) *** 3 (2.4) 
Death or myocardial infarction ≤365 days 8 (1.9) 1 (0.4) 1 (4.3) 6 (4.8) ** 
*=p<0.05, **=p<0.01, ***= p<0.001 when compared to patients with a negative exercise ECG test. 
ECG, electrocardiogram. 
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5.2 STUDY II 
 
5.2.1 Diagnostic sensitivity for MI 
Altogether 911 NSTEMI patients presenting ≤2 hours from symptom onset were included in 
the study. Twenty-four (2.6%) presented with an undetectable level of hs-cTnT. The 
diagnostic sensitivity for MI when using an undetectable level of hs-cTnT at presentation 
with and without information from the ECG is shown in Table 5. The sensitivity was higher 
in patients presenting in the second hour (i.e. >1 hour to ≤2 hours) from symptom onset 
compared to patients presenting within the first hour (i.e. ≤1 hour). The lowest sensitivity was 
found in the subgroup of patients aged ≤65 years without prior MI presenting within one 
hour. The sensitivity improved in all cohorts when ECG was added to the algorithm. 
 
Table 5. Diagnostic sensitivity for MI. Sensitivity when using an undetectable level of hs-
cTnT at presentation, with and without information from the ECG, to rule out MI in a 
NSTEMI population presenting ≤2 hours from symptom onset. 
 Presentation ≤1 hour 
from symptom onset  
Presentation >1–≤2 hours 
from symptom onset 
Presentation ≤2 hours 
from symptom onset 
Sensitivity (95% CI) (n/d) for hs-cTnT at presentation 
All patients (n=911) 94.6 (91.0–97.0) 
(243/257) 
98.5 (97.2–99.3) 
(644/654) 
97.4 (96.1–98.3) 
(887/911) 
Patients ≤65 years, no prior MI 
(n=282) 
86.0 (76.9–92.6)  
(74/86) 
96.9 (93.5–98.9)  
(190/196) 
93.6 (90.1–96.2) 
(264/282) 
Sensitivity (95% CI) (n/d) for hs-cTnT and ECG 
a
 at presentation  
All patients (n=911) 95.7 (92.5–97.8) 
(246/257) 
99.4 (98.4–99.8)  
(650/654) 
98.4 (97.3–99.1) 
(896/911) 
Patients ≤65 years, no prior MI 
(n=282) 
89.5 (81.1–95.1) 
(77/86) 
98.5 (95.6–99.7)  
(193/196) 
95.7 (92.7–97.8) 
(270/282) 
a
 Normal ST-T-findings were defined as the absence of an ST-segment elevation >1 mm (>2 mm in lead V2–
V3), of an ST-segment depression >1 mm in two leads and of a T-wave inversion >1 mm. 
CI, confidence interval; d, denominator; ECG, electrocardiogram; hs-cTnT, high-sensitivity cardiac troponin T; 
MI, myocardial infarction; n, nominator; NSTEMI, non-ST-segment elevation myocardial infarction. 
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5.2.2 Baseline and outcome comparisons 
Compared to NSTEMI patients with a detectable level of hs-cTnT at presentation, patients 
presenting with an undetectable level of hs-cTnT were younger (median age 56 vs. 69 years), 
to a comparable extent male (70.8 vs. 68.9%), less often had a history of MI (12.5 vs. 36.4%) 
and more often presented within the first hour from symptom onset (58.3 vs. 27.4%). A total 
of 62.5% of the patients presenting with an undetectable level of hs-cTnT had a non-ischemic 
admission ECG, compared to 42.6% of the patients presenting with a detectable level, but this 
difference was not statistically significant. 
NSTEMI patients with an undetectable level of hs-cTnT at admission reached a similar peak 
level of hs-cTnT when compared to patients with a detectable level of hs-cTnT at admission 
(median 182 vs. 200 ng/L). No statistically significant difference was seen in the proportion 
of in-hospital coronary angiographies (95.8 vs. 79.7%), revascularization (62.5 vs. 63.2%) or 
death (4.2 vs. 1.6%). Patients in the two groups were to a similar extent discharged with 
acetylsalicylic acid, P2Y12 inhibitors, beta-blockers and lipid lowering drugs. At the 30-day 
follow-up, a total of 95.8% and 62.5% of the patients who presented with an undetectable 
level of hs-cTnT had undergone coronary angiography and revascularization respectively, 
compared to 80.3% and 63.5% respectively of those who presented with a detectable level. 
The 30-day cumulative incidence of death was 4.5 and 3.2% respectively. 
 
5.2.3 Gender differences 
Seventeen men (2.7%) and seven women (2.5%) presented with an undetectable level of hs-
cTnT. Out of these, thirteen men (76.5%) and five women (71.4%) were 65 years or younger 
and did not have a history of MI. The diagnostic sensitivity for MI in men presenting in the 
second hour from symptom onset was 99.5% (95% CI 98.4%–99.9%) (Table 6). In men ≤65 
years without prior MI presenting in the second hour from symptom onset, the sensitivity was 
99.3% (95% CI 96.1%–100.0%). In women, the sensitivity for MI among those presenting in 
the second hour from symptom onset was 99.1% (95% CI 96.7%–99.9%) (Table 7). In 
women ≤65 years without prior MI presenting in the second hour from symptom onset the 
sensitivity was 96.3% (95% CI 87.3%–99.6%). 
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Table 6. Diagnostic sensitivity for myocardial infarction in men. Sensitivity for MI when 
using an undetectable level of hs-cTnT at presentation, with and without information from the 
ECG, to rule out MI in a NSTEMI population presenting ≤2 hours from symptom onset. 
 Presentation ≤1 hour 
from symptom onset 
Presentation >1–≤2 hours 
from symptom onset 
Sensitivity (95% CI) (n/d) for hs-cTnT at presentation 
All patients (n=628) 94.2 (89.8–97.1) 
(178/189) 
98.6 (97.1–99.5) 
 (433/439) 
Patients ≤65 years, no prior MI 
(n=213) 
85.9 (75.6–93.0) 
 (61/71) 
97.9 (94.0–99.6) 
 (139/142) 
Sensitivity (95% CI) (n/d) for hs-cTnT and ECG 
a
 at presentation 
All patients (n=628) 95.8 (91.8–98.2) 
 (181/189) 
99.5 (98.4–99.9)  
 (437/439) 
Patients ≤65 years, no prior MI 
(n=213) 
90.1 (80.7–95.9) 
 (64/71) 
99.3 (96.1–100.0)  
(141/142) 
a
 Normal ST-T-findings were defined as the absence of an ST-segment elevation >1 mm (>2 mm in lead V2–
V3), of an ST-segment depression >1 mm in two leads and of a T-wave inversion >1 mm. 
CI, confidence interval; d, denominator; ECG, electrocardiogram; hs-cTnT, high-sensitivity cardiac troponin T; 
MI, myocardial infarction; n, nominator; NSTEMI, non-ST-segment elevation myocardial infarction. 
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Table 7. Diagnostic sensitivity for myocardial infarction in women. Sensitivity for MI 
when using an undetectable level of hs-cTnT at presentation, with and without information 
from the ECG, to rule out MI in a NSTEMI population presenting ≤2 hours from symptom 
onset. 
 Presentation ≤1 hour 
from symptom onset 
Presentation >1–≤2 hours 
from symptom onset 
Sensitivity (95% CI) (n/d) for hs-cTnT at presentation 
All patients (n=283) 95.6  (87.6–99.1) 
(65/68) 
98.1  (95.3–99.5) 
 (211/215) 
Patients ≤65 years, no prior MI 
(n=65) 
86.7 (59.5–98.3) 
(13/15) 
94.4 (84.6–98.9) 
(51/54) 
Sensitivity (95% CI) (n/d) for hs-cTnT and ECG 
a
 at presentation 
All patients (n=283) 95.6  (87.6–99.1) 
 (65/68) 
99.1 (96.7–99.9)  
 (213/215) 
Patients ≤65 years, no prior MI 
(n=65) 
86.7 (59.5–98.3) 
(13/15) 
96.3 (87.3–99.6)  
 (52/54) 
a
 Normal ST-T-findings were defined as the absence of an ST-segment elevation >1 mm (>2 mm in lead V2–
V3), of an ST-segment depression >1 mm in two leads and of a T-wave inversion >1 mm. 
CI, confidence interval; d, denominator; ECG, electrocardiogram; hs-cTnT, high-sensitivity cardiac troponin T; 
MI, myocardial infarction; n, nominator; NSTEMI, non-ST-segment elevation myocardial infarction. 
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5.3 STUDY III 
 
5.3.1 ED and study population 
During the study period, 3,581 patients visited the ED with a chief complaint of chest pain. 
Hs-cTnT was analysed in 3,169 of these patients. A second sample of hs-cTnT was obtained 
in 1,973 patients out of which 1,397 (70.8%) had the second sample obtained within >30–≤90 
minutes and were included in the study. A total of 1,091 of these patients had a baseline hs-
cTnT level of ≤14 ng/L and were followed 30 days regarding clinical outcomes. In these 
1,091 patients, the median (IQR) value of the first as well as the second hs-cTnT sample was 
<5 (<5 to 7) ng/L. Altogether, 23 patients (2.1%) had a dynamic one-hour change in hs-cTnT. 
The incidence of an index MI among included patients with a baseline level of hs-cTnT of 
≤14 ng/L was 0.5%, compared to 4.2% in all included patients regardless of the baseline level 
of hs-cTnT (n=1397) and 4.4% in all screened patients who were analysed with hs-cTnT 
(n=3169). 
 
5.3.2 Main findings 
A total of 65.2% of the patients with a dynamic one-hour change in hs-cTnT were admitted to 
hospital, compared to 13.9% of the patients with a non-dynamic change (Table 8). Four 
(26.7%) of the patients admitted in the dynamic group had an index diagnosis of MI, 
compared to one patient (0.7%) in the non-dynamic group. In addition, nine of the patients 
admitted (6.1%) in the non-dynamic group were diagnosed with UAP. Eight patients (34.8%) 
in the dynamic group were discharged directly from the ED, but none was diagnosed with 
ACS or readmitted during follow-up and no death occurred. In these eight patients, the one-
hour change in hs-cTnT varied between 3 and 5 ng/L. No ACS or death occurred in the 920 
patients (86.1%) in the non-dynamic group who were discharged directly from the ED. The 
median (min– max range) HEART score value among patients discharged with a dynamic 
change and among those admitted and diagnosed with ACS without a dynamic change was 1 
(0–4) and 5 (4–7) respectively. 
A total of 621 patients with an undetectable level of hs-cTnT at presentation were analysed 
separately. Six patients (1.0%) had a dynamic one-hour change in hs-cTnT. None of the 621 
patients had an index diagnosis of MI and no MI, death or readmission occurred during 
follow-up. One patient (1.6%) in the non-dynamic group had an index diagnosis of UAP. 
Thus, in total, one of the 621 patients (0.2%) with an undetectable level of hs-cTnT at 
presentation was diagnosed with ACS. 
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Table 8. Comparisons of the non-dynamic and dynamic groups with a baseline value of 
≤14 ng/L. A second value was obtained within a time period of >30 to ≤90 minutes, n=1091. 
Variable ∆<3 (n=1068) ∆≥3 (n=23) p 
Age (years) 51.8 ± 16 [1062] 59.8 ± 14.2 0.018 
Male gender 594 (55.6%) 10 (43.5%) 0.240 
Systolic BP (mmHg) 147 ± 25 [1059] 148 ± 27 [22] 0.787 
Diastolic BP (mmHg) 82 ± 12 [1050] 86 ± 17 [22] 0.091 
Heart rate (bpm) 77 ± 16 [1054] 91 ± 27 [22] <0.001 
eGFR (mL/min/1.73 m
2
) 93 ± 23 [1059] 85 ± 19  0.095 
NT-proBNP (ng/L) 105 (38–221) [123] 147 (60–968) [8] 0.436 
Time in the ED (min) 240 (194.5–309) 267 (182–355) 0.487 
Time until attended by physician (min) 75 (38–143) [1058] 30 (21–71) 0.001 
Admitted 148 (13.9%) 15 (65.2%) <0.001 
Myocardial infarction (ICD I21–I22) 1 (0.7%) 4 (26.7%) <0.001 
Unstable angina pectoris (ICD I20.0) 9 (6.1%) 0 1.000 
Angina pectoris (ICD I20.8–9) 12 (8.1%) 1 (6.7%) 1.000 
Atrial fibrillation (ICD I48) 8 (5.4%) 1 (6.7%) 0.590 
Supraventricular tachycardia (ICD I47.1) 2 (1.4%) 1 (6.7%) 0.252 
Unspecified chest pain (ICD R07.4) 70 (47.3%) 6 (40%) 1.000 
Other diagnoses 46 (31.1%) 2 (13.3%) 0.234 
Death within 30 days 1 (0.7%)  0 NS 
Readmission within 30 days due to myocardial 
infarction, unstable angina pectoris or angina pectoris  
0 0 NS 
Readmission within 30 days due to any diagnosis 7 (4.7%) 0 0.502 
Discharged directly from the ED 920 (86.1%) 8 (34.8%) <0.001 
Death or readmission within 30 days due to 
myocardial infarction or unstable angina pectoris 
0  0 NS 
Readmission within 30 days due to angina pectoris  1 (0.1%) 0 NS 
Readmission within 30 days due to any diagnosis  11 (1.2%) 0 0.756 
Data are presented as mean ± standard deviation or median (IQR) or sum and % of the total/ [amount of group]. 
∆ indicates delta; n, total number of patients in the group; BP, blood pressure; bpm, beats per minute; eGFR, 
estimated glomerular filtration rate; ng/L, nanograms/litre; NT-pro BNP, N-terminal prohormone of brain 
natriuretic peptide; ED, emergency department; ICD, international classification of diseases; NS, not significant. 
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5.4 STUDY IV 
 
5.4.1 Study population 
A total of 1,233 patients were included in the study. The 612 patients in phase 1 had a median 
age of 64 years and 57% were male. The 621 patients in phase 2 had a median age of 63 
years and 54% were male. The two groups were similar with regard to most risk factors and 
comorbidities, but prior angina pectoris and revascularization was more common in patients 
included during phase 1. The median time from symptom onset to presentation was 2.8 (1.2–
5.6) and 3.0 (1.6–5.3) hours during phase 1 and 2 respectively. A total of 93% and 91% of the 
patients in phase 1 and 2 had a normal ECG at presentation and 75% and 77% respectively 
had a baseline troponin level within the ULN. The median (IQR) HEART score was 3 (2–5) 
during phase 2. The incidence of an index MI in the study population was 10%. The absolute 
number of MIs was higher during phase 1 (n=83) compared to phase 2 (n=44) but the 
proportion of MIs among patients admitted was comparable between the two phases (23% 
and 22% respectively). 
 
5.4.2 Admission rate 
In the study, the admission rate decreased from 59% during phase 1 to 33 % during phase 2 
(risk ratio [RR] [95% CI]: 0.55 [0.48–0.63]) (Table 9). After adjustment for differences in 
baseline and presentation characteristics, the odds of being admitted were still lower during 
phase 2 (odds ratio [OR] [95% CI]: 0.33 [0.25–0.42]). The difference in admission rate 
remained significant after also adjusting for index MIs (OR [95% CI]: 0.33 [0.25–0.44]). The 
adherence rate to the new algorithm was 87%, and 269 of 308 patients determined as low-risk 
patients during phase 2 were discharged directly from the ED. 
 
5.4.3 Secondary objectives 
The median (IQR) length of hospital stay decreased from 23.2 (4.3–48.2) hours during phase 
1 to 4.7 (3.5–24.7) hours during phase 2 (p<0.001) (Table 9). This was mainly explained by 
the difference in admission rates between the two phases. The median (IQR) estimated 
median health care costs related to each hospital visit decreased from €1,651 (1,019–5,334) to 
€1019 (1,019–2,312) during phase 2 (p<0.001). The reduction was mainly caused by fewer 
admissions and fewer procedures, such as exercise ECG tests and coronary angiographies. A 
total of 3 (0.5%) and 3 (0.5%) patients had an MI after discharge in phase 1 respectively, and 
2 (0.3%) and 0 (0%) patients died after discharge in phase 1 and phase 2 respectively. Two of 
the MIs in both phases occurred in patients discharged directly from the ED. No death 
occurred in patients discharged directly from the ED. 
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Table 9. In-hospital and 30-day outcome (n=1233). 
 Phase 1 
(n=612) 
Phase 2 
(n=621) 
 
RR 
 
95% CI 
 
p 
Admission to hospital  362 (59) 202 (33) 0.55 (0.48–0.63) <0.001 
Time to discharge (h) 23.2 (4.3–48.2) 4.7 (3.5–24.7) – – <0.001 
Health care-related costs (€) 1,651 (1,019–5,334) 1,019 (1,019–2,312) – – <0.001 
New presentation to the ED 78 (13) 81 (13) 1.02 (0.77–1.37) 0.876 
Readmission to hospital 44 (8.0) 36 (6.0) 0.75 (0.49–1.14) 0.175 
Unplanned revascularization 
a
 3 (0.5) 6 (1.0) 1.97 (0.50–7.85) 0.506 
Myocardial infarction after discharge 3 (0.5) 3 (0.5) 0.99 (0.20–4.86) 1.000 
Death after discharge 2 (0.3) 0 (0) – – 0.246 
Persistent chest complaints 212 (39) 214 (37) – – 0.481 
Rating of own health (0–100) 75 (50–85) 75 (50–85) – – 0.819 
Confidence in management (0–100) 90 (80–100) 95 (80–100) – – 0.012 
Data are presented as median (IQR) or n (%). 
a 
Defined as a new presentation to the ED followed by admission and revascularization. 
CI, confidence interval; ED, emergency department; h, hours; IQR, interquartile range; RR, risk ratio. 
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5.4.4 Gender differences 
Men and women were analysed separately regarding the main outcomes of the study (Table 
10). In both men and women, the admission rate, as well as the time to discharge and the 
health care-related costs, were significantly lower during phase 2, compared to phase 1. Men 
seemed to have a somewhat longer stay in the hospital and somewhat higher health care-
related costs during both phases compared to women. The numbers of deaths and MIs after 
discharge were very low in both men and women. 
 
Table 10. In-hospital and 30-day outcome in men and women (n=1230). 
 Phase 1 Phase 2  
Men (n=677) (n=346) (n=331) p 
Admission to hospital  210 (61) 115 (35) <0.001 
Time to discharge (h) 25.0 (4.6–51.2) 4.6 (3.4–27.4) <0.001 
Health care-related costs (€) 1,920 (1,019–6,465) 1,105 (1,019–3,823) <0.001 
New presentation to the ED 46 (13) 44 (13) 0.999 
Readmission to hospital 24 (8.0) 23 (7.2) 0.711 
Unplanned revascularization 
a
 1 (0.3) 5 (1.5) 0.116 
Myocardial infarction after discharge 1 (0.3) 3 (0.9) 0.363 
Death after discharge 2 (0.6) 0 (0) 0.500 
Women (n=553) (n=264) (n=289) p 
Admission to hospital  151 (57) 87 (33) <0.001 
Time to discharge (h) 10.4 (4.2–30.4) 4.7 (3.5–14.4) <0.001 
Health care-related costs (€) 1,522 (1,019–3,030) 1,019 (1,019–2,038) <0.001 
New presentation to the ED 32 (12) 37 (13) 0.809 
Readmission to hospital 20 (8.0) 13 (4.6) 0.103 
Unplanned revascularization 
a
 2 (0.8) 1 (0.3) 0.608 
Myocardial infarction after discharge 2 (0.8) 0 (0) 0.227 
Death after discharge 0 (0) 0 (0) – 
Data are presented as median (IQR) or n (%). 
a 
Defined as a new presentation to the ED followed by admission and revascularization. 
ED, emergency department; h, hours; IQR, interquartile range. 
 
 38 
5.4.5 Patients with a baseline troponin level within normal reference range 
Altogether 461 (75%) of the patients during phase 1 and 476 (77%) of the patients during 
phase 2 had a baseline troponin level within the normal reference range. Fourteen (3.0%) of 
the patients during phase 1 and ten (2.1%) of the patients during phase 2 had an index 
diagnosis of MI (RR [95% CI]: 0.69 [0.31–1.54]). The primary and secondary outcomes of 
this subgroup are shown in Table 11. Of the 363 patients who were sent home from the ED 
during phase 2, two (0.6%) had a subsequent MI of which both had an elevated hs-cTn and a 
HEART score above 3. 
 
Table 11. In-hospital and 30-day outcome in patients with a baseline troponin level 
within the normal reference range (n=937). 
 
 
Phase 1 
  (n=461) 
Phase 2 
(n=476) 
p 
Admission to hospital 
a
 229 (50) 113 (24) <0.001 
Time to discharge (h) 7.5 (3.8–27.9) 4.3 (3.3–6.8) <0.001 
Health care-related costs (€) 1,388 (1,019–2,657) 1,019 (1,019–1,862) <0.001 
New presentation to the ED 51 (11) 51 (11) 0.864 
Readmission to hospital 29 (7.0) 20 (4.4) 0.091 
Myocardial infarction after discharge 3 (0.7) 2 (0.4) 0.682 
Death after discharge 0 (0) 0 (0) – 
Persistent chest complaints 167 (41) 158 (37) 0.167 
Rating of own health (0–100) 75 (60–85) 75 (60–85) 0.927 
Confidence in management (0–100) 90 (80–100) 95 (85–100) 0.011 
Data are presented as median (IQR) or n (%). 
a
 Risk ratio (95% confidence interval): 0.48 (0.40–0.58) 
ED, emergency department; h, hours; IQR, interquartile range. 
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6 DISCUSSION 
 
The introduction of hs-cTn assays in routine clinical care has considerably improved the 
assessment of patient presenting with symptoms suggestive of ACS. Due to the low threshold 
of detection and high precision in the lower measurement range, the time from presentation to 
diagnosis has been radically shortened
3 12 59
. The high diagnostic and prognostic 
performances of these assays have improved the assessment of prognosis in patients 
diagnosed with an MI, as well as in chest pain patients discharged directly from the ED
8 56 57
. 
However, biomarkers alone are not enough to rule out an ongoing ACS. Patient history and 
ECG still play an important role, especially in UAP patients where no alteration of cardiac 
biomarkers is seen
124
. To structure the clinical assessment, clinical risk scores are 
recommended and new scores focusing on low-risk chest pain patients have been validated
3 
101 113 125
. Due to the progress in assessment seen during the last years, the need for admission 
and further testing in chest pain patients now seems unnecessary in many cases
77 78 84
. 
However, there is still limited evidence regarding the new assessment strategies that have 
been developed as a consequence of the new conditions discussed above. With the studies 
presented in this thesis, we aimed to add substantial knowledge to the research field by 
evaluating four approaches to assess patients presenting with symptoms suggestive of ACS in 
the era of hs-cTn. 
 
6.1 THE VALUE OF PREDISCHARGE EXERCISE ECG TESTING  
 
In the first study of this thesis, we evaluated the value of predischarge exercise ECG testing 
in chest pain patients in whom MI had been ruled out by means of medical history, ECG and 
hs-cTnT. The main findings were as follows: no statistically significant difference was seen 
regarding death or MI at 90 or 365 days when comparing patients with a positive and a 
negative predischarge exercise ECG test. In addition, the chest pain cohort studied had a very 
low risk of death and MI during 365 days of follow-up, a risk that was actually comparable to 
that of an age, gender and calendar time-matched cohort from the Swedish population. When 
analysing men and women separately, the findings in outcome were similar. 
The study evaluated predischarge exercise ECG testing as performed in routine clinical care. 
We included a large cohort of chest pain patients equivalent in size with other large-scale 
exercise ECG testing studies, and the distribution between negative, positive and inconclusive 
test results was comparable with previous findings, even though some variation was seen, 
probably depending on differences in baseline characteristic of the cohorts
70 71 73 76 77
.  
Our results confirm the relatively high proportion of false positive tests seen in previous 
studies
69 71
. Out of the 94 patients (9.9%) with a positive predischarge exercise test, less than 
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fifty percent performed a coronary angiography before discharge and 28 (29.8%) were 
revascularized. This suggests that the clinicians did not entirely rely on the test result. No 
increase in death or MI as a consequence of omitting routine invasive evaluation in the 
positive exercise ECG group was seen when compared to the negative exercise test group, 
either at 90 or at 365 days. However, patients with a positive exercise test were to a greater 
extent revascularized when compared to patients with a negative test, both before and after 
discharge. This is expected since it is recommended by current guidelines. Our study cannot 
answer the question of whether the patients’ symptoms prior to revascularization were due to 
CAD or whether revascularization in this non-MI population prevented death or MI
72
. 
Predischarge exercise ECG testing has been recommended as a rule-out strategy in chest pain 
patients as it is simple to perform and has a low complication rate, but also due to its high 
NPV
17 59 69-73
. In our study, only 4 (0.7%) of the patients with a negative exercise test died or 
had an MI within 365 days, indicating a high NPV. But, since the patient cohorts evaluated 
with predischarge exercise ECG testing mainly consists of low-risk patients with a very low 
risk of subsequent death 
70 73 76
 
62
, a high NPV is expected and the pre-test probability of 
having a positive test result is very low. The same low-risk pattern was seen in our study. The 
low incidences of death and MI were not restricted to patients with a negative test, only 7 out 
of 951 patients (0.7%) in the study cohort died or had an MI within 90 days of follow-up. 
In our study, we found that the proportion of false positive tests was high. Moreover, more 
than one quarter of the patients had an inconclusive test result which left the clinician without 
guidance for further assessment. Moreover, there were no statistically significant differences 
in mortality or incidence of MI between patients with a negative and positive test result at 90 
or 365 days of follow-up. Finally, the cohort of chest pain patients had a very low risk of 
subsequent death or MI comparable to the one-year risk of death and MI of a matched 
Swedish population.  
Even though we cannot exclude the possibility of some prognostic impact of variations in 
coronary revascularization rates between patients with a negative and a positive test, our data 
suggest that routine predischarge exercise ECG testing does not provide additional 
information in a chest pain population where MI has been ruled out and the predischarge 
exercise ECG test may, therefore, be unnecessary. Further testing may be considered in 
selected patients but, considering the substantial risk of a misleading exercise ECG test result, 
other non-invasive methods or coronary angiography may be considered. Finally, since most 
hospitals do not provide exercise ECG testing at night and during weekends, this strategy 
could shorten the hospital stay thus reducing the costs. 
 
6.1.1 Limitations 
This was a retrospective study reflecting clinical practice. The decision to refer a patient to a 
predischarge exercise ECG test was not made according to a study protocol, but by the 
attending clinician. The classification of the test result in the study was based on the written 
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clinical conclusion, and the continuous ECG registration was not systematically reviewed. A 
prospective randomization to predischarge exercise ECG testing or a direct discharge, as well 
as the use of a study protocol to analyse the exercise ECG tests prospectively, would have 
provided more reliable results. However, this study reflects the assessment of chest pain 
patients in routine clinical care with its value and limits. The single-centre design may have 
reduced the generalizability of the results. The study was performed prior to the 2013 ESC 
guidelines on the management of stable coronary artery disease recommending risk 
stratification with pre-test probability, and it is possible that some of the exercise tests 
performed would have been omitted after the introduction of these guidelines 
72
. Left 
ventricular function and the use of beta-blockers on the day of the test may have had an 
impact on the exercise test outcome, but these factors were unknown in the study. We 
classified tests without any sign of exercise-induced ischemia at a heart rate of ≥80% of the 
age-predicted maximum as negative, although a cut-off of 85% is conventional
69 70
. However, 
the 85% cut-off has never been validated and previous data suggest that the cut-off could be 
lowered to 80% of the age-predicted maximum heart rate
69 70
. The incidences of death and MI 
were low and a larger population might be required to identify differences between patients 
with a negative and a positive exercise ECG test. Still, the number of patients included in the 
study was equivalent to the number of patients in other large-scale exercise ECG test studies 
and the findings regarding outcome were similar. The registry follow-up was only performed 
within the County of Stockholm and clinical events occurring elsewhere during follow-up 
might have been missed.  
 
6.2 EVALUATION OF A RULE-OUT ALGORITHM IN EARLY PRESENTERS 
 
This is so far the largest study examining the diagnostic performance of the undetectable hs-
cTnT at presentation algorithm in early presenters with a final diagnosis of NSTEMI. There 
has been some uncertainty regarding the safety of using the algorithm within 2–3 hours from 
symptom onset due to the lack of early presenters with MI in previous studies
3 11 93
. With the 
second study of the thesis we aimed to clarify this uncertainty. There is no consensus on 
acceptable sensitivities for MI, even though a sensitivity at or above 99% is often aimed at in 
routine clinical care, as discussed previously in this thesis
119
. Furthermore, little is known 
about the prognosis in NSTEMI patients presenting with an undetectable level of hs-cTnT. 
The main findings of the study were as follows: 
An undetectable level of hs-cTnT at presentation alone did not result in an acceptable 
sensitivity for MI in patients presenting within 2 hours from symptom onset. However, 
combined with a non-ischemic ECG, the diagnostic sensitivity was as high as 99.4% (95% CI 
98.4%–99.8%) in patients presenting in the second hour (i.e. >1 hour to ≤2 hours) from 
symptom onset, indicating that the algorithm might be applied in this population. These 
findings remained when analysing men and women separately. Previous studies have 
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suggested a minimum delay of 2 to 3 hours between symptom onset and presentation when 
applying the algorithm, due to a decreased diagnostic sensitivity for MI found in patients 
presenting earlier
11 86 89
 
90
. Our large cohort of early presenters with NSTEMI enabled a much 
more detailed analysis, as well as the possibility of dividing patients into those presenting 
within the first hour (i.e. ≤1 hour) and those presenting in the second hour. 
An undetectable level of hs-cTnT at presentation combined with a non-ischemic ECG did 
not, however, result in a sufficient sensitivity for MI in patients presenting within the first 
hour from symptom onset (sensitivity 95.7%, 95% CI 92.5%–97.8%). We considered this to 
be due to the fact that the time interval was too short to expect an alteration of hs-cTnT levels 
and serial testing is preferred in this population
3 38 52
.  
Interestingly, we found a decreased diagnostic sensitivity for MI in the subgroup of patients 
aged ≤65 years without prior MI (sensitivity 98.5%, 95% CI 95.6%–99.7%), in patients 
presenting in the second hour from symptom onset. Our findings contradict results of 
previous studies where a similar or improved algorithm sensitivity was reported (similar 
among patients <70 and 70 years91, improved among patients <65 years11 and among 
patients with a non-high risk history, including younger patients and patients who less often 
had a history of MI 
88
). The different results might partly be explained by the fact that these 
studies were not restricted to early presenters. The shorter the time interval from symptom 
onset to presentation, the higher the risk of a false negative hs-cTnT result, and elderly 
patients are in general more likely to present with a hs-cTnT above the LoD which lowers 
their risk of being missed by the undetectable hs-cTnT at presentation algorithm
11 86 91 126
. 
Another explanation might be the low number of NSTEMI patients in these studies when 
compared to our study. In a study focusing on early presenters (<3 hours), the diagnostic 
sensitivity for MI was above 99% when combining an undetectable hs-cTnT at presentation 
with a TIMI score of 0 points (which includes age <65 years)
87
. However, as in the other 
studies referred to, the number of patients with a final diagnosis of NSTEMI was low 
compared to our study, 269 patients had a MACE during follow-up. 
The diagnostic sensitivity for MI among women aged ≤65 years without prior MI presenting 
in the second hour was decreased. However, when analysing men separately, a sensitivity of 
99.3% (95% CI 96.1%–100.0%) was noted. Even though the CI is moderately broad, these 
finding indicate that the algorithm might be applied in men aged ≤65 years without prior MI 
presenting in the second hour from symptom onset. These findings could partly be explained 
by the fact that men in general have higher levels of hs-cTnT, as discussed in Chapter 2.2.3, 
which would then reduce their risk of being missed by undetectable hs-cTnT at presentation 
algorithm. 
Finally, we found that NSTEMI patients admitted with an undetectable level of hs-cTnT at 
presentation were younger but had a similar 30-day outcome to those admitted with a 
detectable level. The peak levels of hs-cTnT and the incidence of revascularization were 
comparable. These findings indicate the importance of identifying NSTEMI presenting with 
an undetectable level of hs-cTnT. 
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6.2.1 Limitations 
This was a retrospective study with a relatively high exclusion rate. A total of 700 patients 
identified as eligible in the SWEDEHEART registry were excluded during the screening 
process in the medical records due to the fact that data regarding time from symptom onset to 
presentation could not be verified. Altogether, 89 patients were excluded due to a type 2 MI 
or a myocardial injury. Since the MI diagnoses in the study were set by the clinicians and not 
all patients underwent coronary angiography, it is possible that some MIs were incorrectly 
classified. However, the validity of MI diagnoses set in routine clinical care in Sweden has 
been reported to be high
127
. The time of taking blood samples may deviate somewhat from 
that stated in the medical records, since the time used was the time when the electronic 
referral for analysis of the sample was sent to the laboratory. For this reason, we chose to use 
the time from symptom onset to presentation to the hospital in the inclusion criteria and the 
analysis of the results. We evaluated the diagnostic performance of the algorithm by 
calculating sensitivity. Specificity, PPV or NPV could not be calculated, since only cases 
with MI were included in the study. However, the aim was to evaluate the safety of the 
algorithm and sensitivity is then considered to be the most important measurement. In spite of 
our large sample of early presenting NSTEMI patients, only 24 presented with an 
undetectable level of hs-cTnT. Since we only included patients admitted, we might have 
missed some NSTEMI patients with an undetectable level of hs-cTnT discharged directly 
from the ED. If these patients presented again, they would then present with a detectable level 
of hs-cTnT, which falsely may have increased the calculated diagnostic sensitivity for MI in 
our study. It is also possible that such patients chose not to present again or died before 
presentation. Unfortunately, neither the SWEDEHEART registry, nor the Swedish patient 
registry could provide data on reinfarction within 30 days, which is why this information is 
missing in the study. Regarding mortality data, a larger population would have been needed 
in order to compare differences in mortality between the groups. 
 
6.3 EXPERIENCES OF A ONE-HOUR ALGORITHM IN ROUTINE CLINICAL 
CARE 
 
The third study of the thesis evaluated some of the consequences of the use of a one-hour hs-
cTnT algorithm when implemented in routine clinical care. The patient population consisted 
of an unselected ED population of chest pain patients with a non-elevated hs-cTnT at 
presentation, which contrasts with several previous studies where the focus has been a more 
selected chest pain population at a higher risk of ACS
13 94 96
 . The main findings of the study 
were the following: in chest pain patients presenting with a non-elevated hs-cTnT, dynamic 
one-hour changes in hs-cTnT were uncommon but were associated with a higher rate of 
admission and of MI. No death or MI occurred among patients discharged directly from the 
ED during follow-up. 
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Dynamic one-hour changes in hs-cTnT occurred in 23 (2.1%) of the patients, while 97.9% of 
the patients had a non-dynamic change. The explanation for the low proportion of patients 
with dynamic changes is partly the fact that we included a large proportion of all patients 
presenting to the ED with chest pain, which also reflects the situation in routine clinical care. 
Even more important is the fact that only patients presenting with a non-elevated hs-cTnT 
were included in the final analysis. This led to a higher proportion of patients in the non-
dynamic group when compared to prior one-hour algorithm studies that included patients 
regardless of the baseline level of hs-cTnT
13 94 96
.  
The difference in admission rate between the dynamic and non-dynamic groups was 
significant (65.2% vs. 13.9%) and suggests that the algorithm was applied by the clinicians. 
The low proportion of admitted patients in the non-dynamic group probably reflects 
assessment with both the one-hour hs-cTnT algorithm and the HEART score, even though 
the HEART score was not systematically evaluated in this study. There was also a significant 
difference in the rate of MI among patients admitted (26.7% vs. 0.7%) when comparing the 
dynamic and the non-dynamic groups. Altogether, 17.4% of all patients presenting to the ED 
with dynamic one-hour changes in hs-cTnT had a final diagnosis of MI, compared to 0.1% of 
the patients presenting with a non-dynamic change. These findings suggest that the algorithm 
could be both useful for rapid rule-in of MI as well as safely applied for rule-out of MI in an 
ED chest pain population, a population with a traditionally high admission rate. In our study, 
the total incidence of MI among those presenting with a hs-cTnT of ≤14 ng/L was low, 0.5%, 
and it has been discussed whether a single presentation value of hs-cTnT of ≤14 ng/L would 
be enough to rule out an ongoing MI. This has, however, been shown to be insufficient
92
. 
Also, the results of the FASTEST study support further evaluation in chest pain patients 
presenting with a hs-cTnT of 14 ng/L, since 24 of the 937 patients (2.6%) presenting with a 
non-elevated troponin had a final diagnosis of MI (Chapter 5.4.5). 
Compared to previous studies evaluating the original one-hour hs-cTn algorithm, the 
incidence of MI was markedly lower in our study
13 14 94 96
. We consider this due to the fact 
that we included an unselected ED chest pain population and only included patients 
presenting with a non-elevated hs-cTnT. The latter reduced the incidence of MI from 4.2% in 
our study population, to 0.5% in the patients included in the final analysis. The MI incidence 
within 30 days of follow-up was only slightly higher (5.4%) in another study focusing on an 
unselected chest pain population in the ED
86
. 
The majority of patients with dynamic one-hour changes in hs-cTnT were not diagnosed with 
ACS and the release of, as well as dynamic changes in, hs-cTnT, were considered to be due 
to diagnoses other than a type 1 MI, which has also been shown in earlier studies
12 36 37 128
. In 
the non-dynamic group, nine of the patients admitted had a final diagnosis of UAP which 
formally goes without an elevation in hs-cTnT levels
124
. However, the median HEART score 
value for these patients and for the one patient with MI was elevated (5 points). This suggests 
not only that patients at an acute risk of a MACE could be identified by the HEART score, 
but also that a careful clinical assessment is needed in patients presenting with chest pain. 
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Finally, none of the 920 patients (86.1%) in the non-dynamic group who were discharged 
directly from the ED died or had an MI during the 30-day follow-up. 
In conclusion, we found that it was possible to implement a one-hour measurement of hs-
cTnT in chest pain patients presenting with a non-elevated value in routine clinical care. 
Moreover, even though early dynamic changes in hs-cTnT were uncommon, the one-hour 
measurement improved the assessment when compared to a single baseline value of ≤14 
ng/L. Finally, a one-hour measurement of hs-cTnT may facilitate an early rule-out of MI in 
chest pain patients, thus reducing the proportion of patients admitted without a final diagnosis 
of MI. However, troponins cannot replace a careful clinical assessment, e.g. with the HEART 
score, especially not in those ACS patients where dynamic one-hour changes in hs-cTnT 
cannot be seen. 
 
6.3.1 Limitations 
This was a single-centre, retrospective study. The single-centre design may have influenced 
the generalizability of the results. The decision to include all patients presenting with a chief 
complaint of chest pain reduced the proportion of patients with high risk of an ACS and an 
evaluation of the algorithm in a more selected population might be of clinical value. 
However, since the population included reflected the patients presenting to the ED in routine 
clinical care, our results could provide results that are more representative of the one-hour 
algorithm when implemented in clinical practice, when compared to previous controlled 
studies. A relatively high proportion of the patients screened had no or only one hs-cTnT 
analysed in the ED. Again, this indicates that the study population was a low-risk population. 
The decision to omit the second sample could be in accordance with the present guidelines 
(e.g. long duration since pain onset, undetectable baseline hs-cTnT, admission without further 
assessment)
3
. Due to the difficulties of obtaining a blood sample after precisely one hour in 
routine clinical care, a time interval of >30–≤90 minutes was accepted. Even though a small 
proportion of the second samples were obtained ≤60 minutes, no MACE occurred in patients 
discharged from the ED. Another challenge in routine clinical care is that the time from 
obtaining the blood sample to the end of the analysis often exceeds one hour. Therefore, it is 
likely that in a large proportion of the patients in the study the result of the first hs-cTnT 
sample was not known when the second sample was obtained. Even though the one-hour 
algorithm was implemented together with the HEART score at the study centre, the HEART 
score was not systematically documented and could therefore not be evaluated in this study. 
Both the incidence of dynamic one-hour changes in hs-cTnT and that of MI was low, and a 
larger population would be needed to evaluate the rule-in part of the algorithm as well as to 
verify the safety of the algorithm. Nevertheless, the excellent safety of the one-hour 
algorithms has been validated in several previous studies
13 96 97
. 
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6.4 EVALUATION OF A ONE-HOUR ALGORITHM AND A RISK SCORE 
COMBINED 
 
In this prospective observational multicentre study, the combination of a one-hour hs-cTn 
algorithm and the HEART score was evaluated for the first time in routine clinical care. Our 
main findings in this fourth study of the thesis were the following: the new algorithm was 
associated with a reduction in admission rates, shorter hospital stays and reduced health care-
related costs, with very low rates of 30-day MACEs. The adherence rate to the algorithm was 
high, 87%. No major differences were seen when analysing men and women separately. 
After the implementation of the algorithm in routine clinical care, the admission rate 
decreased from 59% to 33%. This finding remained after adjusting for differences in baseline 
and presentation characteristics and the number of index MIs between the two study phases 
(OR [95% CI]: 0.33 [0.25–0.44]). The significant decrease in admission rate also remained 
(50% to 24%) when analysing patients presenting with a troponin level within the normal 
reference range, i.e. in those affected by the new algorithm. A previous small single-centre 
RCT using a three-hour measurement of conventional troponin combined with the HEART 
score showed a similar positive effect
111
. The HEART score alone was recently compared to 
standard care in a large, multicentre RCT. In this study, no reduction in admission rate was 
seen, which might be explained by a lower adherence rate (82%) to the HEART score 
strategy in low-risk patients but also to differences in study size and design
103
. 
The median time to discharge was significantly reduced from 23.2 to 4.7 hours. In the above-
mentioned small RCT, the time to discharge was reduced from 21.9 to 9.9 hours
111
. The 
shorter hospital stays seen in our study might be explained by the use of hs-cTn assays, which 
enabled a shorter sample interval. The combination of a two-hour hs-cTn algorithm and a 
modified TIMI score or the EDACS has been shown to significantly increase the number of 
patients discharged within 6 hours without any increase in MACE
6 110 114
. A similar positive 
effect was seen in a small study combining hs-cTn at presentation with the MACS decision 
rule
116
. However, direct comparisons between the new algorithms are limited. 
The reduction in admission rate did not result in longer stays in the ED or an increase in tests 
and examinations after discharge. On the contrary, the proportion of non-invasive tests and 
coronary angiographies was significantly lower during the second phase of the study. A 
similar pattern was noted in a study evaluating the transition from conventional troponin to 
hs-cTn assays in routine clinical care
129
.  
The estimated median (IQR) health care costs related to each hospital visit decreased from 
€1,651 (1,019–5,334) to €1,019 (1,019–2,312) during the second phase of the study. The 
reduced costs were attributed to the lower admission rate and the reduction in diagnostic 
procedures. In the large multicentre RCT evaluating the HEART score, costs were calculated 
over 3 months, which is why we cannot make a direct comparison with our study. However, 
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in the latter study, no cost reduction was seen in the group of patients assessed with the 
HEART score
103
. 
The study was not powered to detect a difference in MACE. However, the rates of MI, death, 
new presentation to the ED, readmission to the hospital and unplanned revascularization after 
discharge were very low in both study phases. No death occurred among patients discharged 
directly from the ED. Two patients (0.8%) in the first phase and two (0.5%) in the second had 
an MI after being sent home from the ED. However, both patients in the second phase had an 
elevated delta troponin and a HEART score above 3, i.e. not considered suitable for rule-out 
according to the algorithm. 
In conclusion, the adding of the HEART score to the one-hour hs-cTn algorithm improved 
the assessment of patients presenting to the ED with symptoms suggestive of an ACS. 
 
6.4.1 Limitations 
This was a prospective observational before-after study where patients were not randomized 
to one of the two assessment strategies. This design implies an elevated risk of bias due to 
differences between the two cohorts that may not be identified and adjusted for, which may 
be associated with the study outcome. There was an imbalance regarding recruitment to the 
two phases of the study. The recruitment rate was low, especially during the second phase, 
which increases the risk of selection bias. Patients in the second phase had a history of 
cardiovascular disease and revascularization somewhat less often and the proportion of index 
MIs was lower during the second phase. Even though adjustments for these differences were 
made in a logistic regression analysis and in a sensitivity analysis, there might still be residual 
confounders that may weaken the association between the study phases and the study 
outcomes. For example, we were not able to adjust for the bed occupancy in the hospitals 
participating. An RCT would have improved the reliability of the results and minimized the 
problem with residual confounders. Conclusions about causality instead of association could 
have been made. However, there is a risk that the assessment strategy in one group would 
influence the assessment in the other group and thereby affect the difference in outcome 
between the two phases. Another, preferable, option would have been a stepped-wedge, 
cluster-randomized trial, but the risk of influence between the two groups would remain since 
our study was performed in a limited geographical region. A second advantage with a 
stepped-wedge cluster-randomized design would be that overall patient consent for the site 
could be obtained, instead of an informed consent from each study participant. This might 
reduce the risk of selection bias at inclusion. However, such a selection bias would most 
probably be non-differential, since it would be the same for the two phases and would hence 
not affect the outcome. 
In addition to the logistic regression analysis, several measures were taken in order to 
minimize the time-dependent differences in the study. The new assessment strategy was 
introduced and implemented immediately after the completion of the first phase of the study, 
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and the second phase started as soon as the new assessment strategy was considered 
implemented. We also analysed patients with a baseline troponin level within the normal 
reference range and with no difference in the proportion of patients with an index MI 
separately. 
The presence of a research assistant in the ED might have increased the clinicians’ adherence 
to the new algorithm, hence leading to a higher adherence rate inside compared to outside the 
study. The study was not powered to detect a difference in MACE, but the safety of the one-
hour hs-cTnT algorithm and the HEART score has been validated in several previous 
studies
13 65 96 97 103
. 
 
6.5  PATIENTS WITH AN UNDETECTABLE LEVEL OF HIGH-SENSITIVITY 
CARDIAC TROPONIN 
 
In three of the studies we evaluated patients with an undetectable level of hs-cTnT, either at 
presentation or as a peak value before discharge. In the study evaluating predischarge 
exercise ECG testing, 445 (46.8%) of the 951 patients included had a peak value of hs-cTnT 
of <5 ng/L combined with a non-ischemic ECG at presentation. This group had an excellent 
prognosis, with only three (0.7%) of the patients reaching the combined endpoint of death or 
MI within a year. In the study evaluating a one-hour hs-cTnT algorithm in the ED the 
findings were similar. In total, one (0.2%) of the 621 patients presenting with an undetectable 
level of hs-cTnT had a final diagnosis of UAP. These findings are supported by previous 
studies evaluating an undetectable level of hs-cTnT or I at presentation and according to 
present guidelines further evaluation of these patients might be omitted after a careful clinical 
assessment
1 3 11 86 90 91
. However, our study including 24 early presenting NSTEMI patients 
with an undetectable level of hs-cTnT at presentation showed that, even though they were 
younger, these NSTEMI patients had a similar 30-day outcome as NSTEMI patients 
presenting with detectable levels. It is, therefore, important to identify patients with an 
undetectable level of hs-cTnT and an elevated risk of a MACE.  
In chest pain patients without a final diagnosis of ACS, there seems to be a graded 
relationship between the levels of hs-cTnT and cardiovascular morbidity and all-cause 
mortality. The risk seems to increase already in patients presenting with a hs-cTnT of 5–14 
ng/L
126 130-135
.  
 
6.6 PRESENT AND FUTURE PERSPECTIVES 
 
In this thesis we evaluated different methods of assessing patients presenting with symptoms 
suggestive of ACS in the era of hs-cTn. The findings of the studies suggest that a more rapid 
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assessment than the ones recommended in the ESC guidelines would be possible. The current 
ESC guidelines suggest predischarge stress testing (exercise ECG testing if stress imaging 
testing is not available) in patients with a pre-test probability of CAD of 15–85% after rule-
out of MI
72
. The results of our first study indicate that routine predischarge exercise ECG 
testing is unnecessary in such a population. Furthermore, due to limited data, the ESC 
guidelines advise against using the undetectable level of hs-cTn at presentation algorithm or 
the original one-hour hs-cTn algorithm within three hours from symptom onset
3
. The findings 
of our second study suggest that a time interval of one hour from symptom onset to 
presentation would be sufficient to apply the undetectable level of hs-cTn at presentation 
algorithm. In the fourth study of this thesis, 50% of the patients assessed with the one-hour 
hs-cTn algorithm combined with the HEART score presented within three hours from 
symptom onset. Finally, the study population in our third study was an unselected ED chest 
pain population, a patient population at a lower risk than the patients included in previous 
one-hour hs-cTn algorithm studies, which contributes valuable information about the 
algorithm when applied in routine clinical care. 
The studies of this thesis were observational. To evaluate the research questions in an RCT 
would improve the reliability of the results and enable conclusions about causality. This 
would increase the possibility of impacting guidelines. 
Several new algorithms have been developed in recent years and direct comparisons, both 
between hs-cTn algorithms and the newly developed risk scores would be of great value. A 
prospective comparison between the HEART score and a simplified version, the HET score 
including medical history, ECG and troponin, would also be of interest. A previous, 
retrospective study found that these three variables were independent predictors of a MACE, 
while age and risk factors were not
5
. In the second study of this thesis, we found that younger 
patients with fewer risk factors of atherosclerotic disease were at a higher risk of being 
missed by the undetectable hs-cTnT at presentation algorithm, which also supports an 
evaluation of the HET score. 
The new hs-cTn algorithms have shown an excellent sensitivity, thus enabling a safe rule-out 
of MI at an early stage. However, the specificity of the hs-cTn algorithms is lower and 
patients ruled in by the algorithms might eventually be discharged without an MI diagnosis. 
This is partly due to the high sensitivity of hs-cTn assays to cardiomyocyte injury, and partly 
to the decision to use the 99
th
 percentile of healthy controls as a cut-off for a non-pathological 
hs-cTn value. New assessment strategies are needed for patients presenting with a discrete 
elevation of hs-cTn but without other findings indicating an MI. 
Measurement of hs-cTn should be combined with a careful clinical examination in order to 
identify ACS patients without elevation of hs-cTn. Further development of safe and easily 
used clinical risk scores would improve the assessment of these patients. 
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7 CONCLUSIONS 
 
Routine predischarge exercise ECG testing had no prognostic value in chest pain patients 
admitted in whom MI had been ruled out by means of medical history, ECG and hs-cTnT. 
An undetectable level of hs-cTnT at presentation combined with a non-ischemic ECG may be 
used to safely rule out MI in patients presenting as early as in the second hour from symptom 
onset. Patients aged ≤65 years without a history of MI should be assessed with caution. 
NSTEMI patients presenting with an undetectable level of hs-cTnT were younger than those 
presenting with a detectable level but had a similar 30-day outcome. 
Early dynamic changes in hs-cTnT were uncommon in an unselected ED population of chest 
pain patients presenting with a non-elevated hs-cTnT, but a one-hour hs-cTnT algorithm 
identified MI patients and facilitated an early rule-out of MI in this population. 
The structured implementation of a one-hour hs-cTn T or I algorithm combined with the 
HEART score in routine clinical care was associated with a reduction in admission rate, time 
to discharge and health care-related costs in patients presenting to the ED with symptoms 
suggestive of an ACS, with very low rates of death and MI after discharge. 
In conclusion, the diagnostic pathways for patients with suspected ACS have been radically 
shortened with the introduction of hs-cTn in routine clinical care. Our findings support the 
use of early rule-out protocols in the ED based on a single baseline value of undetectable hs-
cTn or a one-hour hs-cTn algorithm, preferably combined with a simple risk score. 
Furthermore, our findings support the fact that routine admission, as well as routine 
predischarge exercise ECG testing, can be omitted in this population, a measure that could 
shorten hospital stays and reduce health care-related costs. 
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8 POPULÄRVETENSKAPLIG SAMMANFATTNING 
 
 
Bröstsmärta är en av de vanligaste sökorsakerna vid sjukhusens akutmottagningar. Det är 
också det allra vanligaste symtomet vid akut koronart syndrom (AKS), dvs. hjärtinfarkt eller 
instabil kärlkramp. Traditionellt har ungefär 40 % av bröstsmärtepatienterna som söker akut 
lagts in på sjukhus för vidare utredning men bara 5–20 % av alla sökande får diagnosen AKS. 
Ett fåtal av dem som läggs in får andra allvarliga diagnoser såsom blodpropp i lungan eller 
skada på stora kroppspulsådern, men den stora majoriteten kan skrivas ut med en helt 
godartad diagnos. Å andra sidan visar studier att ungefär 1 % av bröstsmärtepatienterna som 
skickas hem direkt från akutmottagningen drabbas av en allvarlig hjärt- och kärlhändelse 
inom 30 dagar. 
År 2010 introducerades en känsligare mätmetod för att upptäcka hjärtinfarkt vid 
blodprovstagning. Blodprovet kallas högkänsligt troponin och finns i två likvärdiga former: 
högkänsligt troponin T och I vilka frisätts från hjärtmuskeln vid hjärtinfarkt. Istället för att 
som tidigare vänta tre till sex timmar efter att bröstsmärtan startade, kan man nu göra 
blodprovsanalysen redan efter någon timme. Detta har medfört att nya rutiner för 
handläggning av bröstsmärtepatienter har utvecklats, i syfte att så tidigt som möjligt i 
förloppet ställa rätt diagnos. Genom att tidigt bekräfta eller utesluta AKS möjliggörs ett 
förbättrat omhändertagande av bröstsmärtepatienter vid sjukhusens akutmottagningar, där 
behandling för dem med AKS kan sättas in snabbt och patienter utan AKS eller annan 
allvarlig diagnos kan skickas hem direkt från akutmottagningen. Detta är positivt för 
patienterna och optimerar samtidigt utnyttjandet av hälso- och sjukvårdens resurser. 
Syftet med denna avhandling har varit att bidra med ny kunskap inom detta 
forskningsområde genom att utvärdera fyra olika rutiner för handläggning av patienter med 
misstänkt AKS efter införandet av högkänsligt troponin i den kliniska vardagen. 
I den första studien utvärderade vi värdet av arbetsprov på träningscykel inför utskrivning 
från hjärtkliniken vid Södersjukhuset i Stockholm, från januari 2011 till juni 2012 för 
bröstsmärtepatienter där hjärtinfarkt uteslutits med symtombeskrivning, EKG och 
högkänsligt troponin T. Arbetsprov har länge varit en rutinundersökning för dessa patienter 
men nya studier talar för att resultatet ofta är felaktigt eller svårtolkat, vilken kan leda till 
onödig utredning av patienter som i slutänden visar sig vara friska. I vår studie, med 951 
patienter, förelåg ingen signifikant skillnad i antalet dödsfall eller hjärtinfarkter under tolv 
månaders uppföljning när vi jämförde patienter med patologiskt arbetsprovsresultat med dem 
med normalt arbetsprovsresultat. Vi jämförde även alla studiepatienter oavsett 
arbetsprovsresultat med en matchad svensk kohort. Risken för död och hjärtinfarkt inom ett 
år var jämförbar mellan dessa båda grupper.  
I den andra studien undersökte vi huruvida ett icke mätbart värde av högkänsligt troponin T 
(dvs. under detektionsgränsen för mätmetoden) vid ankomst i kombination med ett normalt 
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EKG kunde utesluta akut hjärtinfarkt hos patienter som sökte vård inom två timmar från 
symtomdebut. Via register- och journalgenomgång fann vi 911 patienter som vårdats pga. 
hjärtinfarkt vid fem akutsjukhus i Stockholm 2011–2015, och som sökt vård inom två timmar 
från symtomdebut. Studien visade att man för flertalet patienter med icke mätbart högkänsligt 
troponin T och normalt EKG med hög säkerhet kunde utesluta hjärtinfarkt redan efter en till 
två timmar efter symtomdebut. Däremot var säkerheten otillräcklig för dem som sökte vård 
inom en timme och för yngre patienter utan tidigare hjärtinfarkt. Studien visade också att de 
som vårdades pga. hjärtinfarkt hade en likvärdig 30-dagarsprognos, oavsett mätbart eller icke 
mätbart värde av högkänsligt troponin T vid ankomst. 
I den tredje studien utvärderade vi införandet av entimmesmätning av högkänsligt troponin T 
vid akutmottagningen vid Karolinska Universitetssjukhuset Solna i Stockholm. Den nya 
arbetsrutinen gällde alla patienter som sökte pga. bröstsmärta och som hade ett första värde 
av högkänsligt troponin T inom normalreferensen. Dessa fick lämna ytterligare ett blodprov 
efter en timme. Vi inkluderade 1091 patienter från december 2014 till september 2015 och 
följde dem i 30 dagar. Studien visade att det var ovanligt med ett stigande värde (>2 enheter) 
av högkänsligt troponin T i denna patientgrupp, men att det var associerat med en ökad risk 
dels för sjukhusinläggning, dels för hjärtinfarktdiagnos. Ingen av dem som skickades hem 
direkt från akutmottagningen efter införandet av den nya arbetsrutinen avled eller drabbades 
av hjärtinfarkt under uppföljningstiden. 
I den fjärde studien utvärderade vi effekten av införandet av entimmesmätning av högkänsligt 
troponin T eller I kombinerat med ett enkelt riskvärderingsformulär (HEART score). Studien 
genomfördes vid sex akutmottagningar i Stockholm och Uppsala och var uppdelad i två faser, 
före (juni 2013– september 2014) och efter (januari 2015– maj 2016) införandet av den nya 
rutinen. De två faserna jämfördes med varandra. Totalt inkluderades 1233 patienter vilka 
följdes under 30 dagar. Studien visade att den nya rutinen var associerad med en signifikant 
minskning av antalet sjukhusinläggningar, vårdtid och sjukvårdsrelaterade kostnader. Ett 
mycket litet antal hjärtinfarkter men inget dödsfall inträffade bland de patienter som 
skickades hem direkt från akutmottagningen efter införandet av det nya arbetssättet. 
Sammantaget har denna avhandling bidragit med ny och viktig kunskap om 
omhändertagandet av patienter med misstänkt AKS efter införandet av högkänsligt troponin. 
Vi har visat att arbetsprov inte tillför någon prognostisk information efter att hjärtinfarkt 
uteslutits. Vidare har vi visat att hjärtinfarkt kan uteslutas med ett icke mätbart värde av 
högkänsligt troponin och ett normalt EKG redan efter en till två timmar efter symtomdebut. 
Slutligen har vi visat att entimmesmätning av högkänsligt troponin, gärna i kombination med 
ett enkelt riskvärderingsformulär, förbättrar tidig diagnostik av hjärtinfarkt vilket i sin tur kan 
leda till ett minskat antal sjukhusinläggningar och minskade hälso- och sjukvårdskostnader. 
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